NEWS...Interferon Inc Sciences - Shareholdermeeting - Fusion - 500 Beiträge pro Seite

[Tornado 34]

SPECIAL MEETING OF STOCKHOLDERS

Dear Interferon Sciences, Inc. Stockholder:

You are cordially invited to attend a special meeting of stockholders of Interferon Sciences, Inc. to be held on
March 9, 2004 at 10:00 a.m. local time at 783 Jersey Avenue, New Brunswick, New Jersey 08901. At the special meeting, pursuant to the provisions of the Delaware General Corporation Law, ISI is seeking your approval of the sale of substantially all of our assets to Hemispherx Biopharma, Inc. ("HEB"), as described in the Asset Purchase Agreement (Annex A to this Proxy Statement). Under the Asset Purchase Agreement, ISI will receive 487,028 shares of HEB common stock (which, based upon the closing price of HEB common stock on February 6, 2004, had a value of$1,909,150).


NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO THE STOCKHOLDERS OF INTERFERON SCIENCES, INC.:

NOTICE IS HEREBY GIVEN that a special meeting of the stockholders of Interferon Sciences, Inc., a Delaware corporation ("ISI"), will be held on March 9, 2004 at 10:00 a.m. local time at 783 Jersey Avenue, New Brunswick, New Jersey 08901 for the following purposes:

1. To consider and vote upon the sale of substantially all of ISI`s assets to Hemispherx Biopharma, Inc., a Delaware corporation ("HEB"), pursuant to the Asset Purchase Agreement, dated as of March 11, 2003, by and between ISI and HEB, in the form of Annex A attached to the proxy statement.

___________________________________________________________

Questions and Answers about the Asset Sale
Q: What Will Be Voted On At The Special Meeting? (See Page 24)

A: Pursuant to the provisions of the Delaware General Corporation Law, you are being asked to approve the sale of ISI`s property, plant, furniture, equipment, and all rights to ISI`s ALFERON N Injection, including all intellectual property related to its natural alpha interferon business (the "ISI Assets") to HEB as described in the Asset Purchase Agreement dated as of March 11, 2003, between ISI and HEB, in the form attached as Annex A.

Q: Why Did ISI Enter Into The Asset Purchase Agreement? (See Page 31)

A: After due consideration of all other alternatives reasonably available to ISI, the ISI board of directors concluded that the completion of the sale of the ISI Assets was the only alternative reasonably likely to enable ISI to satisfy ISI`s outstanding obligations and to maximize value to its stockholders and creditors.

Q: What Will Be Received For The Assets Being Sold To HEB? (See Page 35)

A: Pursuant to the Asset Purchase Agreement, HEB will purchase the ISI Assets.
In return for these assets, ISI will receive 487,028 shares of HEB common stock (which, based upon the closing price of HEB common stock on February 6, 2004, had a value of $1,909,150. In addition, HEB will repay approximately $2.5 million of ISI`s indebtedness (which includes approximately $2 million already repaid by HEB).

____________________________________________________________

weitere Infos unter

http://old.edgarpro.com/edgar_conv_html/2004/02/10/000035153…

Bitte genau durchlesen und selbst entscheiden was ein Investment betrifft

Sehr interessant was den ACT deal nach dem Verkauf betrifft

[Tornado 34]

In den letzten 2 Wochen wird ISI wieder kräftig gehandelt.

Durchschnitt / Tag 50K.....
Tendenz steigend....

Assets requires the affirmative vote of a majority of the shares of ISI common stock outstanding at the close of business on the record date. Ms. Margie Chassman owns 16,000,032 shares of ISI common stock, representing approximately 42.9 % of the outstanding common stock of ISI, and has advised ISI that she intends to vote her shares in favor of the sale of substantially all of the assets of ISI

to HEB.

Share Ownership of Management. As of
the record date, the directors and executive
officers of ISI and their affiliates owned
approximately less than 1% of the shares
entitled to vote at the special meeting. All
of the directors and executive officers of
ISI have indicated that they intend to vote
their shares in favor of approval of the
sale of the ISI Assets.

[Tornado 34]

As of September 30 , 2003, ISI had 482 stockholders of record.
On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI.

On March 11, 2003, ISI entered into the Inventory Agreement with HEB pursuant to which ISI sold HEB all of its inventory related to ALFERON N Injection and granted HEB a three year license to sell ALFERON N Injection in the United States. In addition, on March 11, 2003 substantially all of ISI`s employees became employees of HEB. ISI also entered into the Asset Purchase Agreement pursuant to which ISI has agreed to sell its property, plant, furniture, equipment, all customer lists, computer files, data and software, books and records, manufacturing records and procedures, approval processes and approvals with and by the U.S. Food and Drug Administration and all other property, patents, trademarks, and rights of every kind and nature owned or held by ISI relating to natural alpha interferon, its production, manufacture and sale. Upon completion of the Asset Purchase Agreement, ISI will not be involved in the natural alpha interferon business and will not have a manufacturing and research facility. Therefore, ISI`s remaining assets will consist of cash, 586,056 shares of HEB Common Stock (consisting of 99,028 shares currently held by ISI and an additional 487,028 shares of HEB Common Stock to be received upon completion of the Asset Purchase Agreement), a royalty from HEB equal to 6% of sales of products containing natural alpha interferon, a note receivable and a warrant to purchase shares of Amphioxus Cell Technologies, Inc. ("ACT"). ISI does not intend to distribute the HEB Common Stock to the ISI shareholders and has entered into a non-binding Letter of Intent to acquire ACT.

ACT Letter of Intent

On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI. The ACT Preferred Stock will be convertible at the option of the holder at any time, and subject to mandatory conversion if, prior to the date which is two years after the merger, the sum of the proceeds received from (i) the sale of the assets of ISI at the date of merger, and (ii) common equity capital raised at a pre-money valuation in excess of $10 million, exceed $2.5 million.

Certain debt (the "ACT Debt") aggregating approximately $2.9 million that is currently owed to shareholders of ACT will continue as secured non-interest bearing debt of ISI. The ACT Debt will be non-interest bearing and repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment of 25% of the net after tax profits of ACT over $1 million on a cumulative basis. The ACT Debt shall be fully payable upon a change of control of ISI (excluding the transactions whereby the ACT stockholders convert the ACT Preferred Stock). In addition, the ACT Debt shall also be repaid to the extent of the net proceeds from the sale of any equity securities of ISI exceeding $8 million. In addition, certain additional debt aggregating approximately $200,000 owed to a shareholder of ACT will be repayable on the fifth anniversary of the date of the merger.

In addition, preferred stock (the "Junior Preferred Stock") held by a shareholder of ACT will continue as non-accruing preferred stock in the face amount of $2 million, senior in right of preference as to dividends and distributions in liquidation to the ACT Preferred Stock and common stock of ISI. The Junior Preferred Stock will be repayable by ISI on the fourth anniversary of the date of the merger, subject to accelerated payment from 25% of the net after tax profits of ISI available after payment of the ACT Debt. The Junior Preferred Stock will also be subject to reset upon the following conditions: the redemption value and liquidation preference of Junior Preferred Stock shall be increased if either the market capitalization of ISI or the amount to be paid by any third party for ISI values the common stock and any other equity securities or debt convertible into equity securities at (i) greater than $25 million, in which case the Junior Preferred Stock shall be increased to $2.75 million, or
(ii) greater than $35 million, in which case the Junior Preferred Stock shall be increased to $3.5 million (each a "Reset Event"). If not sooner redeemed and paid, the Junior Preferred Stock shall be fully redeemed and retired (subject only to the prior payment of the ACT Debt) at any time upon a change of control of the surviving company (excluding the transaction whereby the ACT stockholders convert their ACT Preferred Stock), or to the extent of the net proceeds from the sale of any equity securities of ISI exceeds $10.9 million.

In addition, on the merger date, three officers of ISI have agreed to grant ISI the option to terminate their employment agreements in exchange for (i) a one-year consulting agreement at the rate of $4,000 per month, (ii) common stock or options exercisable into approximately 1.25% of ISI and (iii) an amount by which 10% of the proceeds from the sale of certain assets of ISI exceed $200,000.

The Letter of Intent is non-binding and subject to the execution of definitive documents and due diligence. However, the parties have agreed to use good faith efforts to negotiate such agreements, and consummate the transaction as soon as reasonably practicable.

Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and Amphioxus have decided not to proceed with a potential transaction unless and until such situation is resolved in a manner that is acceptable to Amphioxus and ISI. In addition, as of the date hereof, neither Amphioxus nor ISI has completed its due diligence and ISI has not received the financial statements of Amphioxus. At such time, if any, that ISI and Amphioxus continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues.

For the reasons set forth above, ISI does not believe the potential transaction between ISI and Amphioxus is probable of completion at the present time. In addition, ISI believes that the failure to complete the asset sale would have a material adverse effect on the ISI stockholders because if the asset sale is not completed, ISI believes that it is likely that it will file for or be forced to resort to bankruptcy protection. In that event, ISI believes that it is extremely unlikely that ISI would be able to pay, or provide for the payment of, all of its liabilities and obligations, and therefore, the ISI Common Stock would have little or no value. See "Risk Factors - Risks Relating to ISI - Failure to Complete the Asset Sale Could Result in Bankruptcy." Unfortunately, because of ISI`s precarious financial situation, ISI believes that the ISI stockholders have but one reasonable choice - to vote in favor of the proposed asset sale to HEB. ISI believes that a vote against the asset sale would lead to the consequences set forth above and preclude the potential transaction with Amphioxus from proceeding . For that reason, ISI believes that the inclusion of financial information regarding Amphioxus would not be material to a stockholder`s voting decision with respect to the asset sale by ISI to HEB.

Relationships between ACT and ISI.

Ms. Margie Chassman owns 16,000,032 shares of ISI common stock representing approximately 42.9 % of the outstanding common stock of ISI. In addition, she has warrants to purchase an additional 16,666,667 shares of ISI common stock. Ms. Chassman also owns 16.65 % of the common stock of ACT. Neither Ms. Chassman nor any designee of Ms. Chassman is a member of the Board of Directors of ISI. Ms. Chassman has no contracts, arrangements, understandings or relationships with ISI with respect to the ISI common stock owned by her. Ms. Chassman has agreed to vote her shares of ISI common stock in the same proportion as the other ISI stockholders vote with respect to any transaction requiring stockholder approval between ACT and ISI

[Tornado 34]

Sollte HEB weiter steigen und der Deal kommt in 4 Wochen zustande........dann gibt es ein kompletten Neuanfang mit guter Einnahmequelle (HEB)

Ich nehme an dass Kurse bei Zualssung des Medikamentes von HEB (Phase 3 beendet ) im 2 stelligen Berreich möglich sind was bedeutet dass ISI über 10Millionen cash bei Verkauf der Aktien besitzt.

Es folgen weitere Vereinbarungen was den Heb deal betriift

ISI besitzt derzeit über 1Million nicht verkaufter HEB-Aktien


Wir werden sehen was passiert.......

IM MOMENT TUT SICH JEDENFALLS WIEDER SEHR VIEL

Now ISI IS BACK TO MAKE HISTORY AGAIN

Grüsse

[Tornado 34]

Kann mir jemand die Differenz zwischen den Charts erklären????????

Big charts.com

[Tornado 34]

Kein Interesse? See you

[Tornado 34]

Ich werde mich nun aus dem Board zurückziehen da mir eh keiner Meinungen schreibt.
Nicht das ich nacher noch schuld bin wenn es nichts wird.........WENN ABER DOCH DANN GEHT DIE PARTY AB

Aktuell 0,04...High 0,05.....

es geht doch....


Grüsse ....melde mich wieder nach dem SHAREHOLDERMEETING

-mal sehen was der Kurs bis dahin macht.

Good Luck
Torni

[Tornado 34]

Achtung.........

Sorry ich kann es nicht lassen........117K

0,06 BBBBUUUMMMMMMMMMMMM

50%%%%%%%%%%%%

[Tornado 34]

Jetzt ist das Teil auf 0,055......+35%

Sagt mal sind da nur Käufer aus USA????

Egal...es fängt erst an

[Tornado 34]

Date - Open- High -Low -Last -Change - Volume % Change
02/11/04´-- 0.0350- 0.0600 -0.0350- 0.0550-- +0.0150 174450- +37.50%


Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Hold
20 - 50 Day MACD Oscillator Hold
20 Day Bollinger Bands Hold

Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 28150

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Hold
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 19348

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Hold
50 - 100 Day MACD Oscillator Hold

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 27317

Overall Average: 56% - Buy

Price- Support- Pivot- Point- Resistance

0.04- 0.03- 0.04- 0.05


Aktuell 0,055

[Tornado 34]

Date - Open- High -Low -Last -Change - Volume % Change
02/11/04´-- 0.0350- 0.0600 -0.0350- 0.0550-- +0.0150 174450- +37.50%


Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Hold
20 - 50 Day MACD Oscillator Hold
20 Day Bollinger Bands Hold

Short Term Indicators Average: 40% - Buy
20-Day Average Volume - 28150

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Hold
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 19348

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Hold
50 - 100 Day MACD Oscillator Hold

Long Term Indicators Average: 33% - Buy
100-Day Average Volume - 27317

Overall Average: 56% - Buy

Price- Support- Pivot- Point- Resistance

0.04- 0.03- 0.04- 0.05


Aktuell 0,055

[Tornado 34]

Das glaube ich gar nicht. Gestriger Anstieg um 37% mit einem absoluten Volumen von 180K auf 0,055
aber was mich wundert ist das sich keiner zu Wort meldet.
Hier ist echt Totenstille und ISI steigt.
Hat wohl keiner Interesse. Nun dann sei es so

Muss ich ja dann auch nichts mehr schreiben.

Also der nächste Anstieg folgt bestimmt. Ich bin der Meinung das es erst so richtig losgeht. Schaut Euch mal das vergangene Jahr an und betrachtet die grünen Striche was die Volumenkäufe betrifft
Also wenn ich das addiere erhalte ich zu 75% versteckte Käufe oder es ist alles nur Mmanipuliert. Was ich aber bei diesen Aussichten nicht glaube.

Gestern hatten wir in kürzester Zeit über 30 Trades bei 0,05 und 0,06 Da hat sich einer eingedeckt.

Also bis dann.....mal ne richtige Meinung wäre nicht schlecht.
Danke und Grüsse

Torni

[Tornado 34]

Einen habe ich aber noch

IFSC - INTERFERON SCI (OTC)
Date Open High Low Last Change Volume % Change
02/11/04 0.04 0.06 0.04 0.05 +0.02 181600 +37.50%



Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest

Short Term Indicators
7 Day Average Directional Indicator Buy Average Strongest
10 - 8 Day Moving Average Hilo Channel Buy Average Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Hold Steady
20 Day Bollinger Bands Buy Maximum Strongest

Short Term Indicators Average: 80% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Strong Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Hold Steady
50 Day Parabolic Time/Price Buy Average Strongest

Medium Term Indicators Average: 75% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Hold Steady

Long Term Indicators Average: 67% - Buy

Overall Average: 80% - Buy

Sicher wollen manche erst bei 0,10 einsteigen

[Tornado 34]

Schaut Euch nur mal das Verhältnis rot -grün an
Das sind nun 7 Monate ....Wer hat da gekauft?????
Also einen kenne ich schon...Ich...

[Tornado 34]

News

Company News and Press Releases From Other Sources:

INTERFERON SCIENCES INC, (SC 13G/A) Statement of Ownership Filed By ALPHA CAPITAL AKTIENGESELLSCHAFT

--------------------------------------------------------------------------------


--------------------------------------------------------------------------------



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*



Interferon Sciences, Inc.

--------------------------------------------------------------------------------

(Name of Issuer)



COMMON STOCK, $.01 PAR VALUE

--------------------------------------------------------------------------------

(Title of Class of Securities)



458903408

--------------------------------------------------------------------------------

(CUSIP Number)


*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


(Continued on following page(s))


--------------------------------------------------------------------------------




Page 1 of 4 Pages



--------------------------------------------------------------------------------


----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Alpha Capital Aktiengesellschaft
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 6,221,089 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 6,221,089 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
6,221,089 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |X|

The aggregate amount in Row 9 represents the maximum amount of shares
that Alpha Capital can beneficially control under a contractually
stipulated 9.9% ownership restriction. The full exercise of Alpha
Capital`s Warrants would exceed this restriction.
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------






--------------------------------------------------------------------------------


CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---

ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.

ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:

783 Jersey Avenue, New Brunswick, NJ 08901

ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Aktiengesellschaft

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Pradafant 7, Furstentums 9490, Vaduz, Liechtenstein

ITEM 2 (c) CITIZENSHIP: Liechtenstein

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value

ITEM 2 (e) CUSIP NUMBER: 458903408

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable

ITEM 4 OWNERSHIP

(a) AMOUNT BENEFICIALLY OWNED: 6,221,089 Shares of Common Stock

(b) PERCENT OF CLASS: 9.9%

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

6,221,089 Shares

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

6,221,089 Shares

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares






--------------------------------------------------------------------------------


CUSIP NO. 458903408 PAGE 4 OF 4 PAGES
--- ---


ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable

ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

Not applicable

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

Not applicable



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

January 26, 2004
----------------------------------------
(Date)

/s/ Konrad Ackermann
----------------------------------------
(Signature)

Konrad Ackermann, Director
----------------------------------------
(Name/Title)





Grüsse

[Tornado 34]

Bald macht es

---BBBUUUMMM-------

[Tornado 34]

@all es wird wieder Zeit sich zu Wort zu melden

Seit meinem ersten Posting das IFSC nach oben geht , hat sich bestättigt das etwas ganz grosses kommen wird

Ich hatte Euch bei 0,03 geraten einzusteigen....Nun sind wir bereits auf 0,06 und waren schon bei 0,07........

ISI steigt und steigt....Ich kann nur raten einzusteigen bevor der grosse run kommt.

Schaut Euch mal ganz genau den Chart an........und den der letzten Jahre...

Viel Erfolg und bis dann.

News gibt es auch schon wieder

www.pinksheets.com Ticker IFSC

[Tornado 34]

buuuuuuummmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm

[Tornado 34]

Achtung

Schon wieder News.........Anscheinend haben da einige grössere Investoren auch Interesse

Buy Buy.........Strong buy


SCHEDULE 13G/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 3)*



Interferon Sciences, Inc.

--------------------------------------------------------------------------------

(Name of Issuer)



COMMON STOCK, $.01 PAR VALUE

--------------------------------------------------------------------------------

(Title of Class of Securities)



458903408

--------------------------------------------------------------------------------

(CUSIP Number)


*The remainder of this cover page shall be filled out for a reporting person`s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


(Continued on following page(s))


--------------------------------------------------------------------------------




Page 1 of 4 Pages



--------------------------------------------------------------------------------


----------------------------- ------------------------------
CUSIP No. 458903408 13G/A Page 2 of 4 Pages
----------------------------- ------------------------------
--------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Celeste Trust Reg.
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) |_|
(b) |_|
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Liechtenstein
--------------------------------------------------------------------------------
5. SOLE VOTING POWER
NUMBER OF 1,467,402 shares of Common Stock
SHARES --------------------------------------------------------
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY None
EACH --------------------------------------------------------
REPORTING 7. SOLE DISPOSITIVE POWER
PERSON WITH 1,467,402 shares of Common Stock
--------------------------------------------------------
8. SHARED DISPOSITIVE POWER
None
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
1,467,402 shares of Common Stock
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES |_|

--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
7.1%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------






--------------------------------------------------------------------------------


CUSIP NO. 458903408 PAGE 3 OF 4 PAGES
--- ---

ITEM 1 (a) NAME OF ISSUER: Interferon Sciences, Inc.

ITEM 1 (b) ADDRESS OF ISSUER`S PRINCIPAL EXECUTIVE OFFICES:

783 Jersey Avenue, New Brunswick, NJ 08901

ITEM 2 (a) NAME OF PERSON FILING: Celeste Trust Reg.

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Trevisa-Treuhand-Anstalt, Landstrasse 8, 9496 Furstentums,
Balzers, Liechtenstein

ITEM 2 (c) CITIZENSHIP: Liechtenstein

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $.01 par value

ITEM 2 (e) CUSIP NUMBER: 458903408

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR
13D-2(B): Not applicable

ITEM 4 OWNERSHIP

(a) AMOUNT BENEFICIALLY OWNED: 1,467,402 Shares of Common Stock

(b) PERCENT OF CLASS: 7.1%

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

1,467,402 Shares

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

1,467,402 Shares

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares






--------------------------------------------------------------------------------

[Tornado 34]

@all

da hier irgendwie kein Interesse besteht sich zu unterhalten werde ich mich nun -in the Underground- of Interferon begeben.

LINKS , NEWS, und die aktuelle Lage wisst Ihr ja nun zu genüge. Mir ist das irgendwie zu doof zu posten und nichts tut sich.

Wer will : per Postfach

Viel Glück ......

P.S Melde mich später dann wieder wenn ich reich bin

Und nicht vergessen Stichtag.......baaaaaallllddddd

[Tornado 34]

Achtung... Nur noch 7 Handelstage
Dann startet die Rakete des Jahres 2004.
Wer jetzt hofft er bekommt noch ISI Aktien billiger der täuscht sich.
Siehe Volumen....heute nur noch 2100........ zu 0,065

Da ist locker von diesem Kurs ein verdreifacher in 14 Tagen drin.

News in Sicht........und nicht nur das.
Wer genau den Chart analysiert der sieht es förmlich.


Grüsse

[Tornado 34]

Achtung es geht wieder mal los

45K bei 0,07 und 45K bei 0,075......der Rest war nur Kleingedrucktes

über 100K und Bid bei 0,065 - ASK o,o75

go Baby go

Da wird gekauft seit Tagen und keiner merkts

Schon mal darüber nachgedacht warum?????

Also IFSC nur noch 5 Handelstage...


Jetzt kommts darauf an

[Tornado 34]

Hemispherx Biopharma Announces FDA Authorization for a Clinical Study with New Biological Alferon LDO for HIV; Company to Initiate Phase II Study in Early-Stage HIV Patients
E-mail or Print this story

2 March 2004, 10:00am ET

PHILADELPHIA--(BUSINESS WIRE)--March 2, 2004--Hemispherx Biopharma, Inc. (AMEX:HEB) today announced the authorization by the U.S. Food and Drug Administration (FDA) to conduct a clinical trial with Alferon LDO(R) in HIV-infected patients. The submission to the Investigational New Drug Application (IND) for "Human Leukocyte Interferon (Alferon N), Oral," ref. BB-IND 3534, allows the Company to initiate a Phase II study of Alferon LDO(R), Low Dose Oral natural alpha interferon, in HIV positive subjects in early stage of disease. The Company expects to initiate the clinical trial in the coming weeks. The trial may be expanded into other life threatening viral diseases.

The objective of the randomized dose-ranging study is to evaluate the safety and activity of orally administered low dose interferon alpha-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be mediators of the natural immune response using cutting edge gene chip technology. Secondary endpoints will include the absolute CD4 count and plasma HIV RNA levels.

In December 2003 the Company announced its manufacturing agreement with Aplicare for Alferon LDO(R). To date, over 100,000 sachets of Alferon LDO(R) are available for use in the study.

Study Design

The study will be an open-label, randomized outpatient study in asymptomatic HIV infected subjects using a range of doses of interferon. Patients will be randomized to receive Alferon LDO(R) in a buffer solution once each day for 10 consecutive days at different doses. The subjects will be randomly assigned to each dose level. Clinical symptoms and adverse events will be evaluated and gene chip microarray analysis evaluations will be made in conjunction with laboratories at Vanderbilt University. The overall duration of the study, in which 60 patients are to be enrolled, will be 6 weeks.

About Alferon LDO and Potential Public Health Enhancement in

Developing Nations

Oral interferon is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster an immune response through the entire body orally. Oral interferon would be much more economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by the this and other emerging viruses (SARS, Ebola, bird flu, etc.). Oral administration of Alferon N(R), with its affordability, low toxicity, no production of antibodies, and broad range of potential bio activity, could be a breakthrough treatment for viral diseases.

About Hemispherx and Public Health

Mentioned Last Change
HEB 3.99 0.09dollars or (2.30%)
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. Hemispherx is committed to clinical development in developing nations. This commitment stems from the vast market size of the untreated patient (approx. 35 Million) and the unique biochemical property (in vitro studies) of Alferon N(R), making this high potency product worthy of this study. A number of the in vitro potency studies have been conducted at Walter Reed National Army Medical Center and published in peer reviewed medical literature. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.

CONTACT: Hemispherx
Investor Relations:
Dianne Will, 518-398-6222

[e-mail]


www.hemispherx.net

[Tornado 34]

Die Weicheier verkaufen und die , die wissen was läuft kaufen.....

Sagt mal wie kann man nur so........sein

Es wird beschlossen das IFSC das Medi an HEB verkauft.
Falls Ihr aber nicht wissen solltet was das heisst:

Heb hat Kurspotential bis xx Dollar. IFSC bekommt von Heb über 1,x Millionen Aktien....das bedeutet das der Cashwert von IFSC weit über 10 MillDollar liegen wird.

Bei 20 Millionen Shares von IFSC bedeutet das einen 2 stelligen Kurs...ach ja Heb hat bereits alle Schulden von IFSC bezahlt und übernimmt auch die restlichen Kosten was Miete, Strom.....ect.betrifft.

Es kommt aber noch besser: Es wurde ein 3 jähriger Vertrieb des Medikamentes von IFSC durch Heb vereinbart. IFSC bekommt davon 6% vom Netto....und nach 3 Jahren ist das Medi wieder bei IFSC.

Diese Vereinbarung des verkaufs an Heb ist nur 3 Jahre gültig....Hallo ....

ich kann nur sagen : Jetzt oder nie........


IHR WERDET ES BEREUEN

[Tornado 34]

Dear Interferon Sciences, Inc. Stockholder:

You are cordially invited to attend a special meeting of stockholders of Interferon Sciences, Inc. to be held on March 9, 2004 at 10:00 a.m. local time at 783 Jersey Avenue, New Brunswick, New Jersey 08901. At the special meeting, pursuant to the provisions of the Delaware General Corporation Law, ISI is seeking your approval of the sale of substantially all of our assets to Hemispherx Biopharma, Inc. ("HEB"), as described in the Asset Purchase Agreement (Annex A to this Proxy Statement). Under the Asset Purchase Agreement, ISI will receive 487,028 shares of HEB common stock (which, based upon the closing price of HEB common stock on February 6, 2004, had a value of $1,909,150).

[weierHai]

Hallo tornado,

na bekommst Du langsam feuchte Hände??? Es dauert ja nicht mehr lange!
Hop oder Top oder doch ein Flop?

mfg
der weiße Hai

[weierHai]

hallo zusammen,

das wars wohl!!
leider nur ein Flop!!!

[Tornado 34]

@weier Hai

Ich bin ganz relaxed... Zu Deiner Information:

Das Meeting läuft bereits und es sieht sehr gut aus

Es fing um 10am..was heisst seit 102 min.
Es muss abgestimmt werden was demnach schon passiert ist.

Meinst Du denn Du bekommst sofort ne Info..oder News von IFSC????? Ne ne Du da wird ganz gezielt gehandelt.

ASK bleibt konstant bei 0,07 stehen.

Ist ja wohl kaum ein Volumen mit 1000 Stück bei 0,045.

Da will wohl jemand die Anleger ungeduldig machen um einzusammeln

Mal sehen wann ne News kommt. Ich denke eher die nächsten Tage....und dann gehts auf und ab

[Tornado 34]

Das ist sowieso kein wirkliches Shareholdermeeting sondern ein...Insidertreffen.

Es gibt nur 2-3 Investoren die die Zukunft von IFSC entscheiden. Und die haben sich schon entschieden als sie den Deal mit dem Kauf der Aktien machten

[Tornado 34]

es gibt für mich nur 2 Thesen...........

: Mrs Chairmann die 42% of IFSC besitzt wurde von HEB beauftragt zu kaufen um den Deal wirklich über die Bühne zu bringen

: Mrs Chairmann wurde von Heb beauftragt dagegen zu stimmen das IFSC Konkurs anmelden muss und Heb bekommt billiger das Medi..wobei da noch andere Mitbieten würden was das ganze teurer macht.

:Mrs Chairmann hatte aber zugesichert 100%ig das Sie für den Verkauf stimmen wird......also wird verkauft

Wer ist überhaupt Mrs Maggie Chair oder Chassman???????

Wir werden es bald wissen

[Tornado 34]

Guten Morgen IFSC

Ich habe da etwas entdeckt.......

Look at the best Bid and Ask

Best Bid: 0.041 (5000 shares)
Best Ask: 0.19 (5000 shares) *



Was geht? Eröffnen wir bald bei 0,20?

[DocDebil]

und - wie ist der Tag heute

[weierHai]

Hallo Doc,

getreu dem Sprichwort Ilse Bilse keiner will se kam der Koch nahm Sie doch!!!

bin mal gespannt was Tornado heute zum Besten gibt!

ein noch hoffnungsvoller weißer Hai

[Tornado 34]

@ the last Morikaner

Hey Ihr zwei...ich kann Euch nur raten die Positionen von interferon nicht zu verkaufen. Wenn doch dann aber bitte mir.....Ich meinte ja bei 0,045

Falls Ihr es bemerkt haben solltet das wir einen Best ASK bei 0,19 hatten. Das heisst das fast keine Verkaufsorders im ASK stehen. Sobald News kommen und da könnt Ihr Euch sicher sein ...Sie kommen....hebt das Teil ab.

Vorausgesetzt es sind die richtigen News. Es hätte schon lange mit hohen Volumen nach unten gehen müssen wenn der Deal geplatzt wäre. Also was schliessen wir nun daraus???????

Der Verkauf war erfolgreich und der Kurs wird künstlich unten gehalten.

Was würde denn wohl passieren wenn wir gestern aufeinmal ein hohes Volumen nach oben gehabt hätten?
Es wären viele aufgesprungen. Nun ist jeder unsicher und ich bin mir fast sicher das bevor wir steigen noch irgend so ein Angsthase verkauft. Oder es wird gedrückt...was aber nicht passt denn ASK steht immer noch und fällt nicht.

Aber nach Börsenschluss steht ein 450% Anstieg im Best ASK was heisst das wenn eine News kommt wir 2 stellig eröffnen.

Da bin ich mir sicher. Ich beobachte IFSC schon zu lange.

Sollte jemand auf die Idee kommen Ifsc mit grösseren Stückzahlen zu kaufen ist es sowieso vorbei und die Rakete startet.

Grund: Jeder will dabei sein

Oder denkt Ihr etwar anderst? Meinungen erwünscht.

Bis bald wenn wir die 0,20er Marke knacken..

[Tornado 34]

Was haltet Ihr von dem Kreuz...........38/200Tageslinie GGGGGGGGGGEEEEEEEIIIIIIIILLLLLLLLLLLLLLLLLLL

[Tornado 34]

Der gestrige ermittelte Kurs um 16.27h war 0,07:-)

also take it easy...........

Wenn jemand Lust hat....ich biete bereits xxK zu 0,05

[Tornado 34]

Das ist doch ein Witz.......0,07+++++55%
Bitte Bitte verkauft doch zu 0,05..... Ich will noch mehr IFSC Aktien......

Mann oh Mann.......

Sagt mal glaubt Ihr mir es jetzt??????????

Wieder 0,07 und bald bei 0,20

Wo sind die Investierten?

Es meldet sich keiner.....das glaube ich echt nicht.

Steht der Wahnsinn noch bevor?

IFSC ist derzeit mehr als 6 Millionen Dollar Wert.......

Das ist der Cash Wert von IFSC......ohne Zukunft.

Normally the Kurs must stand bei 0,16......mindestens

[weierHai]

welcher Schlingel versucht hier mit kleinen Verkaufsorders die IFS Sympatisanten nervös zu machen!!!!

ich habe es im Urin, bald geht` s gehn Norden!
der weiße Hai

[Tornado 34]

Schön das nun auch Du .....weier Hai überzeugt bist.
Ich auch. Wenn man den HEB KURS so betrachtet könnte man fast meinen IFSC verkauft gerade Aktien von HEB

[Tornado 34]

Was soll eigentlich das ständige 0,045 und dann wieder 0,07
Das nervt irgendwie......Gibt es denn nicht eine bestimmte Richtung?

Es ist schon ziemlich ruhig .......was mich aber nicht beunruhigt...Im Gegenteil.....

Wir heben gleich ab

[Tornado 34]

Der Hammer

Lest Euch mal ganz genau ALles durch und dann schliest selber Rückschlüsse...........

Kennt jeder
Company News and Press Releases From Other Sources:

INTERFERON SCIENCES INC files Form DEF 14A, Definitive Proxy Statement
_________________________________________________________
What Does ISI Intend To Do With The Proceeds Generated From The Sale Of HEB Common Stock?

The proceeds generated from the sale of the HEB common stock will be used to repay ISI`s creditors and, assuming ISI completes the transaction described below of which there can be no assurance, to fund the operations of Amphioxus Cell Technologies, Inc. ("ACT"), a biotechnology company that applies liver biology solutions to problems in drug discovery and human therapeutics. On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a subsidiary of ISI) will acquire ACT. The shareholders of ACT will receive preferred stock (the "ACT Preferred Stock") of ISI, convertible into a number of common shares of ISI equal to 75% of the fully diluted capitalization of ISI.

Based upon the outstanding and potential litigation between ISI and HEB described under the captions "Business of ISI - Legal Proceedings" and "Business of HEB - Legal Proceedings of HEB" and the general uncertainty of the current situation with HEB, ISI and ACT have decided not to continue proceeding with a potential transaction unless and until such situation is resolved in a manner that is acceptable to ACT and ISI. In addition, as of the date hereof, neither ACT nor ISI has completed its due diligence and ISI has not received the financial statements of ACT. At such time, if any, that ISI and ACT continue proceeding with a potential transaction, the due diligence process and the evaluation of the financial information will generate issues to be negotiated by the parties, including without limitation the form of any potential transaction and the representation and warranties, conditions to closing, and indemnifications contained in the form of documentation to be utilized in any potential transaction between the parties. There will be no transaction unless all such issues are successfully resolved by the parties, and there can be no assurance that the parties will be able to resolve all such issues. Therefore, ISI does not believe the potential transaction between ISI and ACT is probable of completion at the present time.

Und jetzt kommts
About Amphioxus Cell Technologies
Amphioxus Cell Technologies, Inc. is a Houston-based company that makes liver biology available to the medical marketplace. Founded in 1995, Amphioxus specializes in cultured human liver cell lines with products for high throughput ADME/Tox screening, predictive toxicology, and plasma protein production. Information about Amphioxus is available on the Web at http://www.piercenet.com.



Schaut Euch mal die HP von diesem http://www.piercenet.com.
ganz genau an...........
# # #


For more information contact:
Theodore DeFrank, Pierce
[phone]
[e-mail]

Norman Sussman, Amphioxus Cell Technologies
[phone] X 11
[e-mail]


Ich werde wohl nie mehr verkaufen..........

Grüsse

[Tornado 34]

@all die investiert sind.

Ich denke der Deal ist unter Dach und Fach. Was nun fehlt sind die nächsten News.Nun wie ja bekannt muss IFSC das mit der FDA regeln....Ich nehme an das wenn der Verkauf freigegeben wird oder ist wir endlich die langersehnte Nachricht erhalten.

Wer es schon bemerkt haben sollte.....seit dem 9.März wird kein grösseres Volumen mehr verkauft. Lächerliche 100-1000Stück. Der Bid und ASK nach Börsenschluss ist seit 3 Tagen beachtlich BID 0,041 zu ASK 0,19

Demnach stellt man sich auf einen Run ein Wer aber diese Kurse macht das weis nur der,der sie macht

Ich wünsche allen IFSC`lern ein schönes Wochenende und seid nicht beunruhigt es wird bald im Depot klingeln............

Ja ist denn schon Weihnachten????????

[Tornado 34]

Sie sind da .............News...........................

On March 9, 2004 ISI`s stockholders approved the second asset acquisition.

Wer interesse hat und den Link möchte wo alles drinsteht der schicke mir bitte eine Nachricht in mein Postfach

Grüsse

[Tornado 34]

Datum der Veröffentlichung: Mar 12 2004 6:31PM ET

Also nach Börsenschluss

Mal sehen was am Montag passiert

Aktuell

BID 0,041 - ASK 0,19

Schönen Sonntag

[Tornado 34]

Kein Interesse?

Na mir soll es recht sein.......

[Tschonko]

Hallo Tornado,
sicher besteht Interesse, bin ja auch drinnen.
Warum stellt du den link nicht hier rein?
Ich bewerte das Ask bei 0,19 nicht besonders hoch, ebensowenig wie die Rückfälle auf 0,041.
Ist halt ein alles oder nichts Zock.
Ich bin verhalten optimistisch. Danke für deine Beiträge.

Grüße

[weierHai]

Hallo Tornado,

na wie sieht es aus mit unserem Basisinvestment?

Im moment sind hohe Umsätze zu verzeichnen, jedoch total richtungslos!!!
Oder versucht da jemand schnell Kasse zu machen bevor die Lichter ausgehen? Ich will`s nicht hoffen. Im augenblick sieht es jedoch negativ aus ,045$ !!

Wann kommen nun endlich die Meganews?

der weiße Hai

[DocDebil]

http://www.wallstreet-online.de/si/community/board/threadpag…

Tornado hat vor einem halben Jahr schon mal einen fetten Anstieg angepriesen - doch der blieb trotz seines Countdowns aus. Also - so nett, seine Postings auch sind - zugetroffen hat, seit einem halben Jahr, noch nix.
Ja na, aber die Hoffnung stirbt zum Schluss

[Tornado 34]

Bevor ich hier noch angeklagt werde.....

Hier die Infos

hier der Link http://old.edgarpro.com/edgar_conv_html/2004/03/12/000094664…

IHR findest alles weitere: unter RISK FACTORS.....unter:
- In addition, pursuant to terms of the October Debentures, we are required to acquire ISI`s facility within 90 days from January 26, 2004 and, unless and until we acquire the facility, $1,550,000 of the proceeds from the sale of the October Debentures will be held back. The same condition was in the July Debentures and in the debentures issued in March 2003; however, the holders waived this condition in both debentures. Consummation of the second agreement requires, among other things, approval by ISI`s stockholders. On March 9, 2004 ISI`s stockholders approved the second asset acquisition.

Sehr interessanter Bericht: Kleiner Tipp: Zeit nehmen und die erste Hälfte durchlesen.
Sehr interessant...


Grüsse Torni..........
http://old.edgarpro.com/edgar_conv_html/2004/03/12/000094664…

http://old.edgarpro.com/edgar_conv_html/2004/03/12/000094664…

[Tornado 34]

Jetzt schreibe ich Euch schon den Link und keiner meldet sich...........

Warum schreibe ich überhaupt........????

Mich nervt das selber langsam das IFSC so geheimnisvoll tut

Bei HEB könnt Ihr alles in dem 10K Bericht lesen. Da steht definitiv das zugestimmt wurde....

Da zockt einer......Also ich bin das nicht.......

Fuck Fuck Fuck...wer gibt so billig seine Aktien her.......

[Tornado 34]

Und was mich noch mehr aufregt.....Du kannst bieten was Du willst und bekommst nichts. Da frage iuch mich wer macht diese Kurse......

Ich rufe gleich bei IFSC an......

AAAAAAHHHHHHH ich könnte

[Tornado 34]

Habt Ihr nun den Bericht gelesen?????????? Und Meinungen????????????????

[Tornado 34]

Ich sage Euch da wird manipuliert. Ich hatte seit 1 Std ne Order zu o,o5 stehem umd zwar 50K..... und jetzt wurde ausgeführtt 386 Stück zu 0,045.........

Die Meldung ist erst seit Freitag nach Börsenschluss bekannt und auf einmal gehts mit 60K nach unten....

Ein Witz. Man betarchte die Käufe und Verkäufe......

Ich explodiere gleich......

[Tornado 34]

Scheiss drauf....bald muss IFSC alles weitere bekanntgeben....

Habe ja noch etwas anderes zu tun......

[schlumpfomat]

hi tornado!
sei nicht sauer, daß wird schon, Geduld ist die Mutter
des Erfolgs! Ich ordere auch noch 50k bei 0,041$
ich will ja nicht den Teufel an die Wand malen aber
m.E., sollte mal irgendwas mit Strahlung oder so passieren
, dann sind alle wild auf Jod und ähnl. Zeugs und
bei cancer ist m.E. auch im Bio Bereich noch einiges
Potential siehe pdl und ähnl.
Wenn die dann Kaufpanisch abgeordert werden sind eh alle
kontaminiert und terminiert.
Interferon war doch bisher
so 80er, 90er Jahre ein wirksames Mittel gegen Krebs oder
täusche ich mich da?
ich muß auch noch so einiges aussitzen aber ruhig Blut.
Ich beobachte genügend Kurse um sagen zu können,
die Amis spinnen!
mini orders von 100 Stück mit Gesamtwert von 5 Euro zb.
während ein anderer soeben für den doppelten Preis/Kurs
1 mio stück "gerade noch bekommen hat".
Ich möchte weder belehrend noch langatmig rüberkommen,
aber es ist m.E. nicht sinnvoll schlechtem Geld gutes
nachzuschmeißen, ich spreche aus Erfahrung.
Schau Dir mal mobl,snnw,... paar Teile aus dem Board an
Das mit meinem Szenario oben, wäre selbstverständlich
grausam, es war auch eher eine momentane Stimmung.
gruß

[weierHai]

Hallo Tornado,
nicht traurig sein
alles wird gut!!!
Heute sind schon wieder vorbörslich steigende Kurse im Ask.

Oder versuchst Du etwa den Kurs hochzuziehen!!!!!

bis dann aber die Info deines 175 Seitne Scripts sind interessant, aber wie heißt es doch so schön, Papier ist geduldig. Warten wir mal der Dinge die da kommen sollen.
der weiße Hai

[Tornado 34]

Hallo weier Hai.....

wie meinst Du das vorbörslich ????Habe nichts gesehen und bin erst jetzt online. Also ich war das nicht....

Aber was war denn???

Infos gelesen????

[Tornado 34]

[weierHai]

Hallo Tornado,

habe nur den ersten Teil des Scriptes gelesen. Sollte nur die Hälfte davon zutreffen, so müßte meines Erachtens die Investition in Interferon langfristig ein Glücksgriff sein. Egal was kurzfristig passiert, ich werde meine Aktien bis zum St. Nimmerleinstag halten, vorausgesetzt die Firma geht nicht vorher in die Insolvenz, wird komplett übernommen oder der Kurs steigt so rasant, daß ein Ausstieg ratsam erscheint.
Im Augenblick jedoch ist die ganze Firmenphilosophie nicht gerade Aktionärs freundlich ( vielleicht hast Du ja recht mit deiner Vermutung, daß der Kurs einfach nur künstlihc manipuliert oder niedrig gehalten wird um einige Aktionäre zu verunsichern die dann noch schnell ohne Limit verkaufen.
Die Verbindung zu HEB erscheint mir zumindest sehr vielversprechend, schließlich eröffnet sich dadurch ein größerer Markt durch den Partner HEB. Auch die Produktkombinaton mit HEB erscheinen vielversprechend. Bin gespannt welche News veröffentlicht werden ,sollte die Phase III der FDA Untersuchung abgeschlossen sein. Schließlich ist Alferon ein medizinisches Produkt, was in vielen Bereichen eingesetzt werden kann.

mfg
der weißeHai ( PS Tornado bleib cool unser Basisinvestment wird sich schon noch auszahlen!)

[polyhawk]

Cool ist das Wort des Monats!

Da anscheinend ohnehin nur Maniacs, Subzerozocker und Typen die viel lieber Roulette spielen wuerden, aber leider keinen Schlips besitzen, in Interferon investiert zu sein scheinen...so what it`s not a Blue Chip!

Ich bin und bleibe dabei, aber wenn es in die Hose gehen sollte - I couldn`t care less.

Das Chancenverhaeltnis zum Einsatz ist bei Interferon schon immer unschlagbar gewesen, vielleicht macht sie es ja nocheinmal...

Bei dem Preis kann man mit Spielgeld kaum etwas falsch machen, zumindest besser als Lotto spielen oder auf die Extraterrestrischen zu warten...

Jeder ist seines Glueckes Schmied!

Danke Tornado fuer Deine Postings und halte durch!!

Good luck

cu
POLYHAWK

[Tornado 34]

Hey ich bin doch ganz cool......
Gerade sehe ich das sich der Basiswert von Interferon schon wieder um 11% erhöht hat Hat IFSC nun alle Aktien von Heb flüssig gemacht? Sieht so aus als das Heb wieder steigt

Nur welcher........... verkauft IFSC Aktien...

Sagt mal habt ihr es immer noch nicht kapiert???????????
Der Deal ist bestättigt......das steht in den vorletzten news von Heb....vielleicht sollte man mal lesen...

Zudem kommt da noch mehr Phantasie in IFSC als nur der Verkauf. Es soll einen Deal mit ACT geben und ACT Aktien sollen getauscht werden in IFSC Aktien......

Mann oh Mann......IFSC ist vieeeeeellllllll zu billig

[Tornado 34]

Play the game.......Es ist sooooooooooooooooooo geil.......

Die sind echt sooooooo dooooooofff und Du kannst mit nur ein paar K den Kurs beeinflussen...



Da kannste mal sehen was passieren kann wenn Torni am Rad dreht.......

Danke nochmal 15,5K und sooooooo billig....

So das warsd nun...spätestens am 31 März ist es raus.....offiziell:-)) Ansonsten können wir baden grhrn.

Mann ist doch scheißegal.......Nur Kohle....

[Tornado 34]

HEB läuft gut

[Tornado 34]

Company News and Press Releases From Other Sources:

Interferon Sciences Completes Sale of Assets to Hemispherx Biopharma

NEW BRUNSWICK, N.J., Mar 17, 2004 (BUSINESS WIRE) -- Interferon Sciences, Inc. (ISI) (IFSC - PINK SHEETS) announced today it had completed the sale to Hemispherx Biopharma, Inc. (HEB) of substantially all of its assets including, but not limited to, real estate, machinery and equipment and all of the rights to its natural alpha interferon business.
For these assets, ISI:

(i) received 424,528 shares of HEB Common Stock which has a Guaranteed Value (as defined in the Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without a Guaranteed Value; and

(iii) will receive a royalty equal to 6% of the net sales of any products containing natural alpha interferon sold by HEB (or a Marketing Partner, as defined in the Asset Sale Agreement).

In addition, HEB satisfied certain obligations relating to the real estate, machinery and equipment of ISI which aggregated approximately $ 2,500,000.

The Asset Sale Agreement obligates HEB to register the HEB Common Stock, sets periodic limits on the number of these shares that may be sold and requires HEB to pay ISI an amount equal to the product received by multiplying (i) the number of Guaranteed Shares remaining unsold on March 17, 2006 and (ii) $ 1.59.

The purchase price for the assets was determined by negotiation between HEB and ISI.


Company News and Press Releases From Other Sources:

Interferon Sciences Completes Sale of Assets to Hemispherx Biopharma

NEW BRUNSWICK, N.J., Mar 17, 2004 (BUSINESS WIRE) -- Interferon Sciences, Inc. (ISI) (IFSC - PINK SHEETS) announced today it had completed the sale to Hemispherx Biopharma, Inc. (HEB) of substantially all of its assets including, but not limited to, real estate, machinery and equipment and all of the rights to its natural alpha interferon business.
For these assets, ISI:

(i) received 424,528 shares of HEB Common Stock which has a Guaranteed Value (as defined in the Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without a Guaranteed Value; and

(iii) will receive a royalty equal to 6% of the net sales of any products containing natural alpha interferon sold by HEB (or a Marketing Partner, as defined in the Asset Sale Agreement).

In addition, HEB satisfied certain obligations relating to the real estate, machinery and equipment of ISI which aggregated approximately $ 2,500,000.

The Asset Sale Agreement obligates HEB to register the HEB Common Stock, sets periodic limits on the number of these shares that may be sold and requires HEB to pay ISI an amount equal to the product received by multiplying (i) the number of Guaranteed Shares remaining unsold on March 17, 2006 and (ii) $ 1.59.

The purchase price for the assets was determined by negotiation between HEB and ISI.




So glaubt IHR ES NUN???????

[weierHai]

Hallo Tornado,

gibt es schon irgendwelche Aussagen wie hoch der zu erwartende Umsatz bei HEB mit Alferon sein wird? Das wäre eine interessante Indikation, um die zujunftsaussichten bewerten zu können. Bei 30 Mio Umsatz durch HEB würde der Ertrag bei 6,00% 1,8 Mio $ betragen. pro Aktie 0,048 $. Bei einem KGV von 20 wäre der Kurs demnach 0,96 bei einem KGV von 40 sogar 1,92

So langsam glaube ich unser Tornado hat recht!!
bis dann
der weiße Hai

[Tornado 34]

Endlich hast Du es erkannt.......

Du hast aber vergessen das der Deal mit HEB noch nicht abgeschlossen ist. IFSC ist nun schuldenfrei. Zusätzlich kommt noch der Verkauf der Produktionsmaschinerie.....ect. was IFSC weitere 2,5 Millionen dollar in die Kassen spült

Rechne mal alles zusammen und Du wirst sehen es lohnt sich derzeit zu kaufen

Neue News........Achtung....................

Company News and Press Releases From Other Sources:

Hemispherx Biopharma Completes Acquisition for Worldwide Rights to Alferon N


Company Closes Final Agreement on GMP Certified Manufacturing Facility; Expects International Sales to Begin During the Second Quarter

PHILADELPHIA, Mar 18, 2004 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it has completed the second and final agreement with Interferon Sciences (ISI), including the acquisition of all the worldwide rights on Alferon N(R) as well as an FDA approved biological production facility of 44,000 square feet located in New Brunswick, New Jersey.
On March 11, 2003, Hemispherx Biopharma executed two agreements with Interferon Sciences to purchase certain assets of ISI and consummated the first agreement. In the first transaction, the Company acquired the inventory of Alferon N Injection(R) and a limited license for the production, manufacture, use, marketing and sale of the product.

In the second agreement, the Company acquired all intellectual, proprietary and commercial rights to Alferon N(R) and other assets related to the product including, but not limited to, all real estate and machinery.

"We are excited that we have successfully completed the transaction, which gives us complete ownership of the Alferon N(R) technology," said Dr. William A. Carter, Hemispherx`s CEO and President. "The closing of the agreement allows us to expand the Alferon N(R) Program, which consists of Alferon N Injection(R), Alferon N LDO(R) and Alferon N Gel(R), outside of the United States. We expect to start clinical trials and generate sales with Alferon N(R) internationally in the second quarter of this year."

About Alferon N(R)

Alferon N(R) (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of refractory papilloma infections (HPV) and is also approved for sale by various regulatory agencies worldwide.



Ich gebe nichts mehr her.............

[Tornado 34]

Schaut Euch mal ganz genau den Money Flow an

[Tschonko]

Hallo,
weiterhin kaum nennenswerte Umsätze. Das Warten geht also weiter. Kann noch Monate dauern.
Grüße

[Tornado 34]

Dann warte doch noch Monate

HEB zieht an was den WERT von IFSC auch steigen lässt
Du wirst Dich umschauen wo wir in Monaten stehen...

MAC zeigt Kaufsignal

[Tornado 34]

Company News and Press Releases From Other Sources:

Hemispherx Biopharma Completes Acquisition for......................... Worldwide Rights to Alferon N............................................:-)))))))


Company Closes Final Agreement on GMP Certified Manufacturing Facility; Expects International Sales to Begin During the Second Quarter

PHILADELPHIA, Mar 18, 2004 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it has completed the second and final agreement with Interferon Sciences (ISI), including the acquisition of all the worldwide rights on Alferon N(R) as well as an FDA approved biological production facility of 44,000 square feet located in New Brunswick, New Jersey.
On March 11, 2003, Hemispherx Biopharma executed two agreements with Interferon Sciences to purchase certain assets of ISI and consummated the first agreement. In the first transaction, the Company acquired the inventory of Alferon N Injection(R) and a limited license for the production, manufacture, use, marketing and sale of the product.

In the second agreement, the Company acquired all intellectual, proprietary and commercial rights to Alferon N(R) and other assets related to the product including, but not limited to, all real estate and machinery.

"We are excited that we have successfully completed the transaction, which gives us complete ownership of the Alferon N(R) technology," said Dr. William A. Carter, Hemispherx`s CEO and President. "The closing of the agreement allows us to expand the Alferon N(R) Program, which consists of Alferon N Injection(R), Alferon N LDO(R) and Alferon N Gel(R), outside of the United States. We expect to start clinical trials and generate sales with Alferon N(R) internationally in the second quarter of this year."

About Alferon N(R)

Alferon N(R) (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of refractory papilloma infections (HPV) and is also approved for sale by various regulatory agencies worldwide.

[Tschonko]

Hallo Tornado,
ich hoffe, wir schauen dann bergwärts. Ich bin in IFSC und in HEB drin. Wollte nur wieder mal was von dir hören.
Nicht dass du klammheimlich verkaufst.
HEB steigt und die stehen wie ein Klotz, wir werden schon noch etwas Geduld brauchen.
Grüße

[Tornado 34]

Ja ist ja in Ordnung.Ich bin noch dabei. Verkaufe keine einzige IFSC Aktie.
Gut überlegt...Dein Invest in HEB.Gratuliere. Bin auch bei Heb dabei...IST JA WOHL LOGISCH

AM 31.März........gibts 2,5 Millionen für IFSC
Und zwar cash.....von HEB

[polyhawk]

Ein ueberfaelliges Relisting in irgendein Marktsegment koennte langsam nicht schaden...

Solange der Wert bei den Pink Sheets rumduempelt geht m.E. nichts - please, do it again Interferon.

Trotzdem bleibe ich im Boot, wenn auch skeptisch.

Gruss und good luck

cu
POLYHAWK

[Tornado 34]

IFSC steht kurz vor neuem Anstieg...MAC Kaufsignal...RSI Kaufsignal...was wollt Ihr mehr

HEB derzeit bei 3,80 heisst für IFSC weitere 1,5 Millionen cash bei Verkauf Frage mich nur was IFSC mit den vielen Millionen nun anstellt

Einsteigen...beim nächsten Anstieg 0,12 in Sicht...oder mehr ??????????????????????????????

Jetzt gibts ersteinmal weitere 2,5 Millionen für Maschinen
Wisst Ihr eigentlich das IFSC schon schuldenfrei ist??????
Heb hat auch das bezahlt


Go baby go

[Tornado 34]

Kaum geschrieben gehts schon los???????

Hallo?? Achtung....... 0,07

[polyhawk]

@ Tornado

Hast Du eine Email Kontaktadresse fuer unser Investment parat!?

Via firmeneigener Web-Site funktioniert es leider nicht...
Ich moechte den sogenanten Managern ein paar Fragen bzg. eines Relistings an den Maerkten stellen - so kann es ja kaum weiterlaufen, oder!?

Wir brauchen hier Umsatz und Infos - und keine , oder...

Dank im vorraus und good luck!

cu
POLYHAWK

[Tornado 34]

@poly,

Sie haben Post

[Tornado 34]

[Tornado 34]

Morgen steigt ne Party............

2,5 Millionan Dollar für INTERFERON.......Maschinerie verkauft.
An jedem Produkt was Heb verkauft bekommt IFSC 6% vom Nettoerlös
Ich sagte ja ...an Jedem....

HEB hat nicht nur Ampligen sodern jede Menge Medikamente wo das Produkt von IFSC eingesetzt werden soll.

@Polyhaw.....kannst es wohl kaum erwarten.... Reich wirst Du bestimmt noch , doch nicht über Nacht, da müsste IFSC schon jetzt den Deal bekanntgeben.

Machen sie aber nicht denn sie verhandeln noch.
Welcher Deal??????

A..................C.................T

[Tornado 34]

Schaut doch mal bei Heb unter -News- rein, da gibts Infos bezüglich IFSC

[Tornado 34]

30K bei 0,07

Also alles in allem wurden über 200K zwischen 0,065 und 0,07 gerkauft in nur 2 Wochen.

Wer sagt denn da das kein Volumen sei...

Da wird so gekauft das keiner schnallt was läuft..Meine Meinung.

Grüsse und CIAO

[Tornado 34]

@all die mich vermissen sollten


Bin jetzt die nächsten 2 Wochen im Urlaub......Ich wünsche Euch Alles Gute. Also nicht wundern wenn ich mich nicht melde.

Fliege nach USA...... New York......

Happy Holiday and much money with IFSC........


Welcher Voll... muss den Kurs wieder drücken....grrrrrrr.


Also bis dann

[Tornado 34]

Ihr seid mir ja tolle IFSC Aktionäre. Kaum lässt man Euch mal 2 Wochen unbeaufsichtigt...verkaufen ein paar.
Schön das ich Kauforders gesetzt hatte. Danke fürs einsammeln. Mann oh Mann......

Wisst Ihr schon das Neueste? Heb ist bereits bei IFSC tätig. Es sieht sehr gut aus für die kommenden Monate

Und auch hier gleich noch eine News:

Company News and Press Releases From Other Sources:

Hemispherx Biopharma to Present First Phase 3 Data on Ampligen in Chronic Fatigue Syndrome at the 17th International Conference on Antiviral Research


Primary Endpoint Data Presented at International Conference to be Held May 2-6, 2004

PHILADELPHIA, Apr 13, 2004 (BUSINESS WIRE) -- Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that the Executive Committee of the 17th International Conference on Antiviral Research, to be held in Tucson, Arizona, has accepted the Company`s late breaker abstract, assigned number "LB-5", and scheduled in Oral Session VII on Thursday, May 6, 2004 at 3:45 p.m.
Professor William M. Mitchell, Professor at Vanderbilt University, Department of Pathology, will conduct the presentation. The abstract will disclose the first results obtained from the Company`s phase 3 clinical trial in Chronic Fatigue Syndrome (CFS) with its experimental immunomodulator Ampligen(R), examining the primary efficacy endpoint, physical performance, as determined by treadmill duration.

About the 17th International Conference on Antiviral Research

The purpose of the International Conference on Antiviral Research is to provide an interdisciplinary forum at which investigators involved in basic, applied, and clinical research worldwide can meet to review recent developments in all areas of antiviral research. Specific topics to be covered in the program include synthesis and chemistry, biochemistry and mechanism of action, molecular biology and drug targeting, in vitro evaluation, animal models, pharmacokinetics, toxicology, and clinical trials. Within these areas of interest, there will be invited overview speakers, oral presentations, and poster presentations. The 17th International Conference on Antiviral Research will be held in Tucson, Arizona, USA. All scientific sessions will be held at the Hilton El Conquistador Hotel.

About Chronic Fatigue Syndrome

CFS is well defined by various governmental agencies as a serious debilitating disease in which patients suffer from multiple symptoms, including profoundly disabling fatigue with chronic flu-like symptoms. The U.S. Center for Disease Control and Prevention (CDC) has added CFS to its top priority list of emerging infectious diseases. CFS is estimated to affect over 500,000 people in the U.S., and an equal number in Europe.

About Ampligen

Ampligen is an experimental, double stranded RNA drug acting potentially as an immunomodulator and antiviral. Based on in vitro studies, Ampligen is believed to modulate the immune system as well as inhibit the virus directly. The experimental product is currently in a phase 3 clinical trial for the potential treatment of CFS and in two Phase 2b clinical trials for the potential treatment of HIV/AIDS. The FDA has granted Ampligen Treatment IND Status and Orphan Drug Status.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company`s filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

SOURCE: Hemispherx Biopharma, Inc.

Ich sage nur INTERFERON wird bald durch die Decke gehen.
Da versucht jemand den Kurs nach unten zu drücken und sich einzudecken.

Wer es nicht glaubt schaut einfach in ein paar Wochen wieder rein.

Es war sehr Informativ...auf meiner kleinen Reise

Grüsse und durchhalten...es wird sich lohnen.

[Tornado 34]

ALERT ALERT...............Ich wusste es IHR WURDET ALLE verarscht........


300K bis o,o7........75%%%%%%%%%%%%%%%%%%

[Tornado 34]

Die Reise beginnt..............

Sorry für die Rechtschreibfehler...da werde auch ich ganz nervös..........

286K in nur 2 min..........

[Tornado 34]

Mein respekt...Der MM ist mit allen wassern gewaschen. Das könnte glatt von mir sein

Wahnsinn, endlich mal wieder Volumen

[Tornado 34]

News..........

INTERFERON SCIENCES INC files Form 10KSB, Annual Report

Alles unter IFSC- Pinksheets

[weierHai]

Hallo zusammen,

es gibt gute Neuigkeiten an der IFSC Front.Apr 19, 2004 (streetinsider.com via COMTEX) -- Hemispherx Biopharma, Inc.
(AMEX: HEB) said results of an independent study, conducted by the Genome
Institute of Singapore, suggests that its lead drug, Alferon N Injection,
exhibits the most potent antiviral activity in an in-vitro model of SARS-CoV
infection and is a potential drug for in vivo research.



bis dann
der weiße Hai
Tornado heut war ich aber schneller!!!

[weierHai]

Hallo IFSC Gemeinde,

jetzt geht`s los!!!!!!!!!!!!!!! Biotechnology Conference; Background on New Phase 3 Clinical Data on CFS to be
Presented


Health/Medical Writers / Business Editors
White Mountain Capital Biotechnology Conference
PHILADELPHIA--(BUSINESS WIRE)--April 20, 2004
Hemispherx Biopharma, Inc. (AMEX:HEB) announced today
that Dr. William A. Carter, CEO and President, will present at the
Second Annual White Mountain Capital Biotechnology Conference. The
event takes place Thursday, April 22nd at the Rihga Royal Hotel in New
York City and the presentation is scheduled for 2:40 p.m. EST.
Dr. Carter will provide an overview of commercial progress with
Alferon N Injection(R), a natural source Alpha Interferon, and
clinical progress with the Company`s experimental immunotherapeutic
Ampligen(R). Dr. Carter will also provide an update on 2004 milestones
and recent activities that support the expected NDA filing of
Ampligen(R) for the potential treatment of Chronic Fatigue Syndrome
(CFS). During the presentation, Dr. Carter will also compare the study
design of the successful AMP 502 CFS study (available at the Company`s
website) with the current AMP 516 phase 3 study, including patient
demographics, duration, dosage and clinical endpoints.

About White Mountain Capital

White Mountain Capital is a full-service investment firm serving
individuals, corporations and institutions. In addition to its
broker-dealer services, it provides clients with proprietary,
independent research on select biotechnology companies.

Dies lief soeben über Bloomy
na dann auf steigende Kurse kann man nun fast blind wetten oder etwa nicht!!!???

der weiße Hai

[DocDebil]

"jetzt gehts los"... das hab ich schon sooo oft hier gelesen

Also noch zwei Monate, dann muss der Kurs mindestens bei 14 €cent stehen - ansonsten werde ich wohl noch länger auf den Interferons sitzen...

[Tornado 34]

HEB derzeit bei 4Dollar.....
Bei IFSC wird nichts mehr verkauft.....

Habt Ihr den letzten Anstieg von 0,037 auf 0,07 in nur 2 min. gesehen????
So wird es auch bald wieder sein.

Schaut Euch mal den Money flow, MAC und RSI an...
Beim nächsten Anstieg 0,15 und dann gehts erst richtig los.

Nun wird derzeit bei IFSC über den Deal mit ACT gesprochen.

Grüsse

[Tornado 34]

HEB über 5 Dollar
IFSC jetzt billig....da wird gesammelt. Bald Ausbruch und Durchbruch...dont sell

Torni

[weierHai]

Hallo Tornado,

lange nichts mehr von Dir gehört.

durch den starken Kursanstieg von HEB müßte rein rechnerishc der Kurs von IFS bei ca. 0,20 USD liegen. Teile deine Meinung en Titel ja nicht zu veräußern!!!!

auf ein gutes Gelingen
der weiße Hai

[weierHai]

Hallo IFSC Gemeinde,

per 05.05.04 gabs eine neue Veröffentlcihung zu IFS. Darin enthalten waren die Gehälter der Führungsriege. Desweiteren wurde die Aktionärsstruktur mit Gewichtungen über 5,00% gewichtet. Dabei fällt auf daß Miss Chassmann 42,90 % der Aktein hält. Übt diese Frau noch die ihr zustehenden Optionen aus so erhöht sich ihre Gewichtung auf 60,50 %.

Wer ist diese Frau? Kann jemand was zu ihrer Motivaton sagen, so stark in IFSC engagiert zu sein? Diese hohen Einzelbeiteiligungen bergen auch gewisse Risiken!

Trotz alledem werde ich abwarten was die Zukunft so bringt. Die Umsätze sind im Moment ja mehr als dürftig. Still ruht der See!!

mfg
der weiße Hai

[Tornado 34]

Achtung IFSC fängt wieder mit steigenden Umsätzen an sich auf den Weg nach oben zu machen....Wie weit das weis wohl keiner

Gestern 20K
Heute 30K

oder mehr????????


Grüsse


Aus bekannten Kreisen weis man das diese gewisse Miss Chassman eine interessante Person für IFSC ist

[Tschonko]

Hallo,
das Ding ist so was von zaaach! Diese Warterei nervt.
Eigentlich müssten die ja schon Geld haben.
Könnten doch wenigstens melden, dass an einer anderen Firma Interesse besteht.
Tschonko

[Schoeneck]

HI

Tja das ist eine Geduldsprobe. Hauptsache sie kommen irgend wann und
verschwinden nicht irgend wo !!!!

Dann warten wir mal weiter… und weiter … und weiter.

Gruß Manuel

[Tornado 34]

Achtung..... Es stehen News an.....

STRONG BUY...........

[DocDebil]

Weil Interferon einfach nicht in die Hufen kommt kaufe ich nun mein Auto auf Kredit.
Tja, die Zahlung geht 3 Jahre - vielleicht kann ich dann die Schlussrate mit den Interferons bezahlen...

Oder in drei Jahren wird Tornado bei einem Kurs von 0,05 immernoch von "strong buy" und "NEWS kommen" schreiben

[Tornado 34]

Nicht Jammern sonder -Kaufen- dann steigt auch der Kurs.
Alles klar?

[DocDebil]

Pfffffff - mir damit einer seine 0,03 gekauften zu 0,07 an mich verkaufen kann?!? nee, den job soll ein anderer machen. ich meld mich in 3 jahren, wenn ich die schlussrate überweisen muss. dann sollte interferon sich verdreifacht haben. damit ist dann alles abbezahlt

[Tornado 34]

Was sagt Ihr jetzt?

INTERFERON SCIENCES INC files Form NT 10-Q, Notification of Late Filing
May 14 2004 5:04PM ET
INTERFERON SCIENCES INC files Form 10QSB, Quarterly Report of Financial Condition
May 14 2004 4:49PM ET

Es kann aber keiner behaupten ich hatte nicht recht.

[Tornado 34]

Kann mal einer kaufen????

Nur keine Panik....bald wird gekauft

[Schoeneck]

Tja, wenn du mir Geld gibst, dann kaufe ich. :-)
Aber bis jetzt haben mir Aktien eh kein glück gebracht. Bin mit einer sogar mit 90 % - dabei.
Warum sollte man also noch mehr anlegen und dann auch noch wenn man kaum was hat!!!!

Gruß

[polyhawk]

@ Tornado

Gruess Dich!
Ich werde definitv kein Stueck mehr kaufen, bevor unser Baby nicht das Pink-Sheet-Segment verlassen hat.

Ausserdem sind die letzten getreuen m.E. bereits gut positioniert und saturiert - warten wir es ab.

Good luck

cu
POLYHAWK

[Schoeneck]

Hi Leute

Was ist den eigentlich das Pink-Sheet-Segment ?!?
Ich kenne mich mit dem ganzen Zeug nicht aus.
Hatte die Aktien mal von einem Freund empfohlen bekommen vor 5 Jahre.

Danke für die Aufklärung

Gruß
Schöneck

[Tornado 34]

Ich denke das wars dann wohl

[Tschonko]

Hallo Tornado,
hab keine neuen Meldungen gefunden. Was hat sich geändert,
außer dass IFSC jetzt bei 0,04 steht.
Hast du was gehört oder bist einfach nur angfressn?

Grüße Tschonko

[Tornado 34]

Mich nervt das hin und her irgendwie...Zudem kommt einfach keine News, was auch deuten könnte das weiterhin gar nichts mehr passieren wird. Das würde heissen das IFSC nur noch ein leerer Mantel wäre.

Das gibt mir zu denken.

[Tschonko]

Ja, das mit dem leeren Mantel ist ein gutes Bild.

Aber in dem Mantel ist noch Geld. Alferon ist verkauft, sie haben nichts außer dass HEB Schulden bezahlt hat und sie haben HEB Aktien und kriegen einen Anteil am Alferon Geschäft. Bitte korrigieren, wenn ich falsch liege.

HEB hab ich verkauft zu 3€, damit einmal ein Gewinn da ist.
IFSC ist ja auch nicht leicht zu verkaufen, weil kaum Umsätze. Wichtig wäre, dass sie den Deal mit ATC machen oder sonst eine Ankündigung, dass sie wen übernehmen wollen.
Aber vielleicht sind sie dazu gar nicht mehr in der Lage?
Müssen wahrscheinlich weiter warten.
Tornado, wie schätzt du die Situation ein?

Tschonko

[weierHai]

Hallo Tornado,

was ist nur los mit unserem "Basisinvestment"? Wir marschieren stark auf die Unterstützungslinie auf 0,00 $ zu!
Irgendwie ist das alles nicht mehr nachvollziehbar, denn in letzter Zeit wird durch HEB US ständig auf die guten Aussichten mit dem Produkt Alferon von Interferon verwiesen.
Was ist bloß los???
Welche Meinung habt Ihr zur aktuellen Lage

mfg
derweiße Hai.

[Tornado 34]

Hallo,

na was soll man dazu nun sagen? Ich dachte das in den nächsten Tagen eine News bezüglich ACT kommen wird und das der Quartalsbericht nun endlich kommt. Doch irgendwie werde ich das Gefühl nicht los das IFSC gar kein Interesse mehr hat weiterzuarbeiten. Ich meine es war mit ACT ein NON-BINDING letter. Also nur eine Vereinbarung. IFSC hat bestätigt das sie das Geschäft im März 2005 wieder aufnehmen wollen..Hmm die Frage ist nur ob dann noch handelbar.
Das Teil nervt mich echt und ich habe einen Teil verkauft.

Was nun passieren wird weis wohl keiner. Mich wundert es nur das niemand mehr kauft..

Denke es ist nun vorsicht angesagt.

Grüsse

[weierHai]

Hallo IFSC Gemeinde,

am 23.06.2004 ist HV beiHemispherx Biopharma Inc. Da kann man nur hoffen, daß endlich positive Meldungen in Bezug auf Vermarktung von Alferon bekannt gegeben werden.
Ich werde irgendwie den Verdacht nciht los, als ob gezielt versucht wird den Kurs Richtung 0 zu drücken. Denn da sind wir usn doch hoffentlcih einig die Vereinbarung mit HEB ( so die Zahlen und Fakten der Wahrheit entsprechen) haben sich bisher in keinster Weise im Kurs durchgeschlagen.

Ich glaube man versucht mit dieser Masche die Aktionäre zu verunsichern um die Aktien wieder billig einsammeln zu können. Die Umsätze in den letzten Tagen sind ja wohl ein schlechter Scherz.
bin für Meinungen zu diesem Thema dankbar
der weiße Hai

[Tschonko]

Hallo weierHai,
es ist mysteriös. Keine nachrichten, nichts. Was tornado schreibt, ist auch möglich. Wann laufen den die Zahlungen an. HEB hat ja mal die Schulden beglichen.
Wunschkonzert: HEB soll abgasen, dann käme da auch wieder etwas Schwung rein.

Tschonko, ahnungslos

[weierHai]

Hallo IFSC Gemeinde,

wasgeht hier bloß ab??? Erst geht heute dr Kurs unter 3 Cent zum Schluß wird der Kurs auf Vortagesniveau hochgezogen. Mit einem Umsatz von 225000 Aktien relativ hoch. Aber irgendwie hab ich so langsam den Eindruck die Amis wollen uns verarschen. Wie Tornado bereits mehrfach ausführte ist lt. News die Firma schuldenfrei ( Übernahme durch HEB US) zuzüglich 1,2 oder 1,4 mio Shares dieser Gesellschaft. Der Wert müßte demnach locker 12 bis 15 Cent aufweisen ohne die vereinbarten Lizenseinnahmen, welche nach Ablauf von 3 Jahren wieder an IFSC zurückübertragen werden.
Ich glaub wir müssen mal in die Staaten fliegen und den Verantwortlichen dieser myteriösen Informationspolitik verbunden mit dem nicht nachvollziehbaren Kursverlauf mal richtig in die Eier treten.
Eine Unvershcämtheit wie man hier als Aktionär behandelt wird.

Tornado was hälst du davon mal direkt mit dem Management in Kontakt zu treten? Hast du vielleicht eine Kontaktperson? Oder wie kann man direkt mit der Firma in Kontakt treten. Denn ich finde so langsam ist das Maß voll.

bleibe jedoch weiterhin investeirt. Bei diesen Kursen ist es wie in der Lotterie!
bis dann
der weiße Hai

[Tschonko]

Hallo,
hab versucht etwas zu finden. Keine Chance! Sogar die Homepage ist aufgelöst. http://www.interferonsciences.com[/URL]
Ich glaube, die haben nichts mehr vor. 3 jahre sind lang.
Natürlich können die Hauptinvestierten unten billig einsammeln und warten, was HEB macht. Aber das sind nur vage Vermutungen. Bleibe aber auch noch drin.
Tschonko
PS: Tornado auch vom Winde verblasen?

[Tornado 34]

Hallo weißer Hai ,

ich habe vor einer Woche versucht das Managment welches derzeit aus 4 Personen besteht zu kontaktieren.

Es gibt da noch die alte Telefonnummer :
Address:
783 Jersey Ave.
New Brunswick
NJ 08901-3660
USA
Phone: [phone]

Leider ist da niemand von Interferon mehr zu erreichen. Es meldet sich die Com box von HEB. Also gehe ich davon aus das nicht mal mehr ein Büro besteht.

Daraufhin habe ich mich mit Heb in Verbindung gesetzt und die wussten gar nicht was ich wollte und wer IFSC sein soll. Ist wohl alles ein schlechter Scherz.

Meine Meinung:
Ich denke das IFSC kurz vor der Pleite stand und der Firma nichts anderes übrig blieb als das Geschäft an Heb zu verkaufen. Mitarbeiter von IFSC wurden komplett zu Heb transferiert.
IFSC hat die erhaltenen Aktien von Heb schon im Dez. 03, April 04 zu flüssigem Kapital gemacht.

Das heisst das IFSC nun keine Aktien mehr von Heb besitzt und das Kapital sich bei einem der 4 Managern befindet.

Fazit: Keine Maschinen mehr, kein Büro, keine Schulden, also eine sogennante AUFLÖSUNG....was jetzt noch bleibt ist ein leerer Mantel.

Weis selber nicht wie lange das Pink sheets noch mitmacht.
Insolvenz gibt es auf jedenfall keine, doch ob es weitere Neuigkeiten gibt das weis ich auch nicht.

Ich habe das selbe bei Micrologica erlebt. Am ENDE ...NICHTS
Ob die Lizenzen in 3 Jahren zurückgeführt werden das ist wohl noch nicht so klar, denn es wurde Alles an Heb verkauft.

Ich denke ein weiteres Investment ist dringend abzuraten bevor es keine Neuigkeiten gibt.
Am besten zu Höchstkursen raus und abwarten.

Kannst ja mal versuchen anzurufen.....

Bin derzeit in OSEE INVESTIERT und lasse IFSC links liegen.

Schönes Wochenende

[Tschonko]

Form 10QSB for INTERFERON SCIENCES INC

16-Jun-2004
Quarterly Report

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

ISI was incorporated in 1980 and until March 11, 2003, ISI was abiopharmaceutical company which studied, manufactured, and sold ALFERON NInjection(R), a highly purified, multi-species, natural-source alpha interferonproduct (the "Product"). ALFERON N Injection is approved by the FDA for thetreatment of certain types of genital warts and has been studied for itspotential use in the treatment of human immunodeficiency virus ("HIV"),hepatitis C virus ("HCV"), and certain other indications. ISI has experiencedsignificant operating losses since its inception.

On March 11, 2003, ISI executed two agreements with HEB to sell certainassets of ISI. In the First Asset Sale Agreement, ISI sold all of its inventoryrelated to ALFERON N Injection(R), ISI`s natural alpha interferon productapproved for the treatment of certain types of genital warts (the "Product"),and granted a limited license for the production, manufacture, use, marketingand sale of the Product in the United States. In the Second Asset SaleAgreement, which was consummated on March 17, 2004, ISI sold to HEB all of itsrights to the Product and other assets related to the Product including, but notlimited to, real estate, machinery and equipment.

On October 17, 2003, ISI and Amphioxus Cell Technologies, Inc. ("ACT")entered into a letter of intent pursuant to which ISI (or a wholly ownedsubsidiary of ISI) will acquire ACT. ACT is a biotechnology company that appliesliver biology solutions to problems in drug discovery and human therapeutics.The letter of intent is non-binding and subject to the execution of definitivedocuments and final due diligence. (See Note 10).

Liquidity and Capital Resources

For the assets transferred to HEB pursuant to the First Asset SaleAgreement, ISI received 487,028 shares of HEB common stock and a royalty equalto 6% of the net sales of the Product. As of December 31, 2003, ISI sold all487,028 shares of HEB common stock and realized net proceeds of $1,207,000. Inaddition, until October 31, 2003, ISI received a service fee for providingcertain transitional services to HEB and HEB assumed $408,000 of ISI payablesand certain other obligations related to the Product.

For the assets transferred to HEB pursuant to the Second Asset SaleAgreement, which was consummated on March 17, 2004, ISI:

(i) received 424,528 shares of HEB Common Stock which has a Guaranteed Value (as defined in the Second Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without

a Guaranteed Value; and
(iii) will receive a royalty equal to 6% of the net sales of any products containing natural alpha interferon sold by HEB (or a Marketing Partner, as defined in the Second Asset Sale Agreement).
As of May 6, 2004, ISI has sold 287,400 of the 487,028 shares of HEBcommon stock and realized net proceeds of approximately $ 1,200,000. Based onthe closing price of HEB on May 6, 2004, the remaining 199,628 shares of HEBcommon stock received pursuant to the Second Asset Sale Agreement had a value of$ 848,000. In addition, HEB satisfied certain obligations relating to the realestate, machinery and equipment of ISI which aggregated approximately$2,500,000.

The Second Asset Sale Agreement sets periodic limits on the number ofthese shares that may be sold and requires HEB to pay ISI an amount equal to theproduct received by multiplying (i) the number of guaranteed shares remainingunsold on March 17, 2006, and (ii) $ 1.59. The remaining guaranteed shares willthen be returned to HEB.

In March 2003, the Company sold 15,000,000 shares of its common stockin a private placement transaction to an investor for $150,000. In connectionwith this private placement, the Company also sold a warrant to purchase15,000,000 shares of common stock, exercisable at $.01 per share and expiring inMarch 2008.

In June and July 2003, the Company received $100,000 and issuedconvertible notes payable to private investors. The notes are due June 30, 2004and bear interest at the rate of 6% per annum. Each note is convertible into theCompany`s common stock at a price of $.06 per share. During August and September2003, the Company repaid $65,000 of such notes.

At May 6, 2004, the Company had approximately $ 1,759,000 in cash andcash equivalents. Until utilized, such cash and cash equivalents are beinginvested principally in short-term interest-bearing investments.

Based on the Company`s sale to HEB, estimates of revenue, expenses, andthe timing of repayment of creditors, management believes that the cashpresently available and the net proceeds from the sale of the remaining 199,628shares of HEB common stock owned by the Company will be sufficient to enable theCompany to continue operations through March 31, 2005. However, actual resultsmay differ materially from such estimate, and no assurance can be given thatadditional funding will not be required sooner than anticipated or that suchadditional funding will be available when needed or on terms acceptable to theCompany. Insufficient funds will require the Company to curtail or terminateoperations.

The Company participates in the State of New Jersey`s corporationbusiness tax benefit certificate transfer program (the "Program"), which allowscertain high technology and biotechnology companies to transfer unused NewJersey net operating loss carryovers to other New Jersey corporation businesstaxpayers.

During December 2003 and 2002, the Company completed the sale ofapproximately $3.4 million and $6.5 million of its New Jersey tax losscarryovers and received $0.28 million, $0.53 million, which were recorded as again on sale of state net operating loss carryovers on the Company`sConsolidated Statements of Operations in 2003 and 2002, respectively. In June2004, the Company, if eligible (which the Company currently is not), will submitan application to sell an additional approximately $1.7 million of tax benefits(calculated by multiplying the Company`s unused New Jersey net operating losscarryovers through December 31, 2000 of approximately $19.1 million by 9%). Theactual amount of such tax benefits the Company may sell will depend upon theallocation among qualifying companies of an annual pool established by the Stateof New Jersey. The allocated pool for fiscal year 2004 is $40 million.

The Company`s Common Stock is traded in the over-the-counter market andquoted on the Pink Sheets, which may have a material adverse effect on theliquidity of its Common Stock and on its ability to obtain additional financing.

Results of Operations

Three Months Ended March 31, 2004 Versus Three Months Ended March 31, 2003

For the three months ended March 31, 2004, the Company recorded $14,740 inroyalty income from HEB. For the three months ended March 31, 2003, (i) theCompany had revenues from the sale of ALFERON N Injection of $241,637, and (ii)the Company recorded revenues of $1,149,112 from the bulk sale of the remainingAlferon inventory to HEB.

Through March 10, 2003, the Company sold, through its distributor, towholesalers and other customers in the United States 1,980 vials of ALFERON NInjection. After March 10, 2003, HEB took over the distribution of Alferon NInjection from the Company.

Cost of goods sold and excess/idle production costs totaled $267,054 forthe three months ended March 31, 2003. Excess/idle production costs representedfixed production costs, which were incurred after production of ALFERON NInjection was discontinued in April 1998. After March 10, 2003, HEB took overcertain operating costs of the Company.

Research and development expenses during the three months ended March 31,2003 were $176,091. After March 10, 2003, HEB took over certain operating costsof the Company.

General and administrative expenses for the three months ended March 31,2004 were $273,394 as compared to $265,972 for the same period in 2003.

Interest income (expense), net, for the three months ended March 31, 2004was income of $6,890 as compared to expense of $118,665 for the three monthsended March 31, 2003. The decrease of interest expense was primarily due to theinterest, including amortization of debt discount, on the convertible notespayable during the three months ended March 31, 2003.

For the three months ended March 31, 2003, the Company recorded service feeincome from HEB of $121,251.

For the three months ended March 31, 2004, the Company recorded a gain onthe sale of assets to HEB of $2,875,282.

For the three months ended March 31, 2004, the Company recorded $ 52,470 ofincome tax expense based upon the alternative minimum tax for federal taxpurposes.

As a result of the foregoing, the Company earned net income of $2,571,048and $684,218 for the three months ended March 31, 2004 and 2003, respectively.

Forward-Looking Statements

This report contains certain forward-looking statements reflectingmanagement`s current views with respect to future events and financialperformance. These forward-looking statements are subject to certain risks anduncertainties that could cause actual results to differ materially from those inthe forward-looking statements, including, but not limited to, the risk that theCompany will run out of cash and the uncertainty of obtaining additional fundingfor the Company, all of which are difficult to predict and many of which arebeyond the control of the Company.

Werd nicht ganz schlau draus. Ist aber wohl so ähnlich, wie tornado gesagt hat. Die haben nichts mehr vor.
Was sit von Bedeutung?
Tschonko

[Tornado 34]

Hallo,
habe gerade das Szenario gelesen. Nun wer will kann warten. Mir reichts. Habe nun lange genug gewartet.
Ich denke das die Chefs nichts mehr machen werden und sich zurückziehen.
Ich meine sie bekommen nun von jetzt an ständig 6% vom Verkauf des Medikamentes durch Heb.
Ist wie eine Rente......warum sollen die noch etwas machen...

Fuck...für mich wars das.

Adios IFSC.....

[Tornado 34]

Seht Ihr...Keiner hat interesse noch zu kaufen.

Na dann...Good bye

[Tschonko]

Meine waren heute so was von schnell weg. Hat mich echt gewundert. Bei 0,03 kauft noch wer.
Mit Gewinn von HEB bin ich mit Miniverlust raus.
Aber das war mir zu lästig.

Grüße Tschonko

[weierHai]

Hallo zusammen,

habe versucht den Quartalsbericht zu lesen. Ein absolutes Chaos um hier einen sauberen Überblick zu erhalten. Ständig wurden neue Bonds emittiert in Verbindung mit Wandlungsrecht in Aktien... Hier die Zahlen in Kürze, welche ich aus dem Bericht recherchiert habe.
Die Gesellschaft hatte 138 mio $ Schulden. Durch den Verkafu an Heb reduzierte sihc der Verlust auf 135,4 mio $.
Die Gesellschaft hat nun noch knapp 200.000 HEB Aktien. Lt. Quartalsbericht streicht das Management ca 280000 $ pro Quartal ein. Lt Bericht würde auf aktueller Kursbasis HEB dies bis ca. 31.03.2005 reichen. Im ersten Quartal hat HEB ca. 241000 mit Alferon Produkten umgesetzt 6% ergeben demnach 14750 $. Um zukünftig allein die Managmentgebühren zu decken, müßten ca. 5 mio $ pro Quartal umgesetzt werden, um allein die Führungsriege zu bezahlen. Wie Torando schon schrieb eine sichere REnte!! Aber was passiert nach der Rückübertragung der Lizenz am 17.03.2006???
Zusätzlich sollten noch irgendwann die Schulden zurückgeführt werden. Dazu müßten aber die Umsätze mit Alferon deutlich höher liegen. Desweiteren wurden noch eine Kapitalverflechtungen so z.B per17.10.2003 mit Amphioxus Cell Technologies Inc vereinbart, eine spätere Übernahme nicht ausgeschlossen.
Das Finanzgeflecht und die Strategie sind für einen Außenstehenden nicht zu durchschauen.

Trotz alledem bei dne aktuellen Kursen werde ich nicht verkaufen! Die 6% fließen auf jeden FAll bis 17.03.2006. Und danach?
Vielleicht höhere Umsätze mit Alferon und eventuell eine höhere Quote als 6%.

Ich werde trotz allem den Verdacht nicht los, daß der Kurs bewußt gedrückt wird um die Aktionäre zum Verkauf zu bewegen. Warum wäre sonst wie bei Tchonko der Trade in diesem illiquiden Wert doch so schnell abgewickelt worden!

Meines Erachtens steckt in der Produktvermarktung von Alferon noch sehr viel Musik!

jetzt spiel ich eben russisches Roulette. Hop oder Top!

Meinungen erwünscht

der weiße Hai

[Tornado 34]

Bin komplett draussen....Mir ist die Zukunft zu heiss
Leerer Mantel?????

Das weis nur IFSC

Good Luck

[Tschonko]

Hallo Hai,
du dürftest schon Recht haben, dass der Kurs gedrückt wird.
Siehe gestern, da verkauft einer 100!!! Stück, um den Kurs von 0,035 auf 0,025 zu drücken. Eindeutiger geht es nicht.

Die ganze Geschichte ist halt sehr halbseiden. Ich wünsch dir viel Glück und viel Geduld. Ich überlege mir, vielleicht wieder HEB reinzunehmen, was vielleicht bei dir als Absicherung auch zu überlegen wäre.
Grüße Tschonko

[polyhawk]

@ Tornado

Wenn Du mal eine echt grosse Wurst sehen moechtest - schau einfach in den Spiegel, alter Doofpusher!

Ich bleibe dem Wert erhalten, denn nur wer wagt gewinnt...

Allen investierten good luck und gute Nerven!

cu (not Tornado)

POLYHAWK

[Schoenecker]

Es gibt ja hier noch leben. :-) Ich habe u viel gewagt und bis jetzt zu viel verloren. :-) Aber ich warte noch auf Zeichen und Wunder. Und wenn es erst am 2005 sein sollte.
Schönes Wochenende

Gruß Manuel

[DocDebil]

Hab mir mein neues Auto jetzt von Genentech-Aktien gekauft. In 5 Jahren vielleicht wieder ein anderes - hoffe dass Interferon dann mal über 0,14 € ist... Wenn nicht, dann in 10 Jahren - solange halten Autos ja...

[Schoenecker]

10 Jahre wäre gut da läuft mein Vertrag aus von meinen Schulden. Somit hätte man dann ein Häuschen und das schuldenfrei. Vielleicht geschehen auch noch Zeichen und wunder und es steigt wie vor 5 Jahren. Dann ist sogar noch ein Ausbau drinnen. Aber warten wir mal ab …

[weierHai]

Hallo IFS Gemeinde,

vielleicht hilft diese Meldung der Aktie mal mit einem Schub nach oben_!


Spekulative Anleger schauen sich heute einmal HEMISPHERX BIO an - schon im vergangenen Jahr machte die Aktie dank spektakulärer Kaufempfehlungen einzelner Analystenhäuser auf sich aufmerksam!
HEMISPHERX bietet therapeutische Produkte zur Behandlung von HIV und für das chronische Erschöpfungssyndrom CFS an. Hoffnungsträger ist dabei das experimentelle Medikament Ampligen. Laut Analysten-Schätzungen soll der Umsatz bei Ampligen für die Anwendungsbereiche HIV und CFS schon im ersten Jahr USD 160 Mio. betragen, nimmt man an, dass lediglich eine Marktpenetration von 0.5 Prozent durchzusetzen ist.
Experten bemessen die Wahrscheinlichkeit einer Marktzulassung für Ampligen in den USA und Europa auf rund 90%. Demzufolge kamen in den vergangenen Monaten Kaufstudien mit Kurszielen bis USD 25 in Markt – bei einem derzeitigen Kurs von USD 2.75 noch immer ein Potenzial von rund 800%! Da steckt also eine gehörige Portion Optimismus drin, aber selbst bei Kursanstiegen in den Bereich USD 8-12, die wir in den kommenden Monaten durchaus dem Titel zutrauen, wären Kurspotenziale zwischen 200 und 350% auszuloten! Klingt abenteuerlich, mit einer kleinen spekulativen Position können Sie diesen heißen Ritt aber wagen, denn in den vergangenen Tagen kamen nun wieder richtig gute News in den Markt, was sich dann auch gleich im Kurs bemerkbar machte:
Mit dem Baylor College of Medicine in Houston ist HEMISPHERX BIO eben bei der Entwicklung von Ampligen in eine Kooperation eingetreten. Diese Einrichtung wird bei der Erforschung von Krebs- und Gen-Therapien mit mehreren Millionen Dollar vom National Health Institut unterstützt. Gestern nun meldete man, dass man Ampligen auf Anfrage der Behörden in Singapur nun auch zur Behandlung der SARS-Infektion testen wird. Zusammen mit dem Genome Institut of Singapore wird man zudem das Medikament Alferon gegen SARS testen.
mfg
der weiße Hai

[Schoenecker]

Und was heißt das für IFS?!?
Danke Manuel

[weierHai]

Hallo IFS- Gemeinde,

hat schon jemand den Quartalsbericht per 30.09.2004 vom 15.11.04 analysiert!
Hab leider keine Zeit. Vielen dAnk für die Infos im voraus.

der wieße Hai

[weierHai]

Hallo zusammen,

was gibt es positives zu vermelden?
Konnte nichts im Quartalsbericht entdecken. Dei Umsätze jedoch steigen in den letzten TAgen. Kurs gestern ,035$!

Weiß jemand ob demnächst was ansteht??

die Ruhe vor dem Sturm!

schönes Wochenende

der weiße Hai

[weierHai]

Hallo Tornado,

wo bleiben deine Kommentare????
Ich glaub unser "Baby" wird bald groß rauskommen!!
BIOWIRE2K
PHILADELPHIA--(BUSINESS WIRE)--Nov. 22, 2004


Experimental Effort to Prevent Sudden Spread of Dreaded Viruses
in Large, At Risk Populations

Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that the
institutional review board of Hong Kong has approved a protocol for a
randomized, dose-ranging study of Alferon(R) LDO (Low Dose Oral
Interferon Alfa-n3 (Human Leukocyte Derived)) in normal volunteers
and/or asymtomatic subjects with exposure to a person known to have
SARS or possible SARS. This clinical study has been approved by the
Clinical Research Ethics Committee of the Kowloon West Cluster at the
Princess Margaret Hospital in Hong Kong.

mfg
der weiße Hai

[weierHai]

Hallo IFS Gemeinde,

zunächst noch alles gute für 2005! Vielleicht schafft es unser Baby dieses Jahr mal au den pushen zu kommen:
Schaut euch mal HEB US an. Dortwerden unter aktuelle Produkte diverse Alferon Komponenten aufgelistet. DA die Lizenzen ja nur ausgeliehen wurden ( Stichtag 17.03.2006) sollte IFS dank der positiven Kommentare zu Alferon doch davon profitieren. Bin auf den Umsatz HEB gespannt. Schließlich erhält IFS daraus 6,00% Umsatzprovision.
Und nach dem 17.03.2006 ist alles wieder bei IFS.
Auch der Vergleich mit Konkurrenzprodukten sieht eigentlich sehr vielversprechend aus.

wäre für Kommentare und Meinungen dankbar
( Tornado lange nichts mehr gehört!!!, warte auf deine bekannten Infos!)
mfg
der weiße Hai

[armselig]

Hallo erstmal,
in diesem thread ist ja nicht viel los....
naja bei IFS ja auch nicht und zu nichts kann man auch nicht viel schreiben
Gestern hat IFSC ja mal eingeatmet.Sind bei Yahoo zwei Report draußen, anscheinend haben sie wohl einige im Ami Land bewegt zu kaufen.Leider kosten die Reports Geld.

Das Geld wäre mir IFSC dann auch noch schuldig
Aber evtl steigen einige schon ein mit Blick auf 2006
Mal weiter abwarten
Gruß

[ICELINE]

Hab mit Interferon im letzten Jahr als reines Zockerpapier ins Depot geholt und verfolge das Forum seitdem. Es hat sich bisher ja noch nicht viel getan. Jetzt steht die Aktie ja zumindest schon mal bei 0,07 USD.

Hat das einen bestimmten Grund ? Können wir hier jetzt bald mehr erwarten ?

Wäre dankbar füe eure Kommentare.

[polyhawk]

@ ICELINE

Userinfo
Username: ICELINE
Registriert seit: 21.03.2005 [ seit 2 Tagen ]
User ist momentan: Offline
Letztes Login: 21.03.2005 20:35:10 [ seit 2 Tagen ]
Threads: 0
Postings: 1 [ Durchschnittlich 0,4565 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen
Interessen: keine Angaben


Welcome Back ???


@ All

Meine Stocks werden schoen im Depot bleiben, bis sich wirklich was bewegt. Die Aktie ist m.E. Hop oder Top - das investierte Geld (Peanuts) habe ich bereits abgeschrieben. Mein Feeling ist allerdings gut (abgesehen von der gebotenen Skepsis). Begruendung: Interferon war immer extrem - und ich war noch nicht mit dabei, noch nicht!

What Ever

cu
POLYHAWK

[Schoenecker]

Was ist mit IFS los?! Gibt e da news???

[armselig]

@schoenecker
keine Ahnung, habe die Aktie schon fast vergessen...
und werde sie auch so lange vergessen bis wir 2006 schreiben.Vielleicht sind das ja schon die Vorwehen für 06
Gruß

[armselig]

Bin mir zwar nicht sicher aber ich habe es so verstanden,dass Albuferon eine Weiterentwicklung von Alphaferon ist also ein Interferon Produkt ist.
Na mal sehen
Gruß
Quelle:www.reuters.com


Human Genome Sciences Hepatitis C Drug Passes Test
Thu Apr 14, 2005 03:52 PM ET
Printer Friendly | Email Article | Reprints | RSS
Top News
White House, U.S. Capitol emptied in plane scare
Military punishes key Abu Ghraib scandal figure
Pakistan says not to hand top Qaeda member to U.S.


MORE

NEW YORK (Reuters) - Human Genome Sciences Inc. on Thursday said its experimental drug for hepatitis C met its primary goal in a mid-stage trial of patients who had not previously been treated for the liver-damaging virus.
The Rockville, Maryland-based company said the favorable results were seen in a trial of 56 patients with the genotype 1 strain of hepatitis C, the hardest to treat of three main strains, who were given varying doses of its Albuferon injectable drug. The patients had never previously been treated for their condition.

Albuferon is a laboratory-altered form of interferon-alpha, a standard treatment for hepatitis C. But unlike standard interferon treatments that must be injected once weekly, researchers said the Phase II trial indicated Albuferon is highly effective with injections only every two to four weeks.

Patients taking the two highest doses of the drug saw their levels of virus decline by over 99.9 percent 28 days after treatment began. That satisfied the trial`s primary goal of showing at least a 99 percent reduction in virus, meaning a reduction to undetectable levels, after four weeks.

The company said 69 percent of patients in those two high-dose groups achieved the 99 percent reduction of virus after four weeks. Undetectable virus levels after 42 days were seen in 23 percent of the same patients.

Swiss drugmaker Roche sells the most popular interferon, called Pegasys, which is taken with a pill called ribavirin to treat the often-deadly virus. Schering-Plough Corp.`s interferon, called Peg-Intron, is also taken alongside ribavirin.

Those standard combo treatments are considered the best available therapies for the virus, but use of them for up to 48 weeks only knocks down the virus to undetectable levels in about 42 percent of patients with genotype 1, Human Genome Sciences said.

Based on the promising results of its Phase II trial, Human Genome Sciences said it plans to conduct a larger 48-week mid-stage trial pairing Albuferon with ribavirin. The trial will pit the combo treatment against either the Roche or Schering-Plough combination therapy in patients with genotype 1.

David Stump, head of drug development for Human Genome Sciences, told Reuters he hopes Albuferon, when paired with ribavirin, will supercede the Roche or Schering-Plough combo in effectiveness as well as tolerability.

"If we show superiority in the head-to-head trial, we would become the new gold standard of treatment," he said.

© Reuters 2005. All Rights Reserved.

[armselig]

auszug aus www.hgsi.com
How Albuferon Was Created

Albuferon was created using Human Genome Sciences` proprietary albumin fusion technology. Albumin fusion technology allows scientists to create next-generation protein drugs by fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein. Albuferon results from the genetic fusion of human albumin and interferon alpha.

Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for over twenty days. Research has shown that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins.

[weierHai]

Hallo IFS Gemeinde

unser Baby hebt so langsam ab, da müßte so langsam der News Flow einsetzen.

bis dann
der weiße Hai

[armselig]

@weierHai
Hallo,
ich dachte schon das wird hier ein Selbstgespräch.
hast du eine Idee warum sie steigt??
Gruß

[Schoenecker]

HI Leute

Ich hoffe doch, das es losgeht, wie vor 7 bzw. 8 Jahre. Dann kann ich endlich mein Garten neu machen!!!! :-)

Gruß Manuel

[ICELINE]

Hallo IFSC-Freunde,

bin mir auch nicht ganz sicher ... Liefert Interferon Science eine der Komponenten für Albuferon ?

[polyhawk]

@ Longies

Ich glaube wir scheinen tatsaechlich einen erneuten Inter-Hype zu erleben!
Ich habe mich in der Vergangenheit immer in den Selbigen gebissen habe, weil ich nicht dabei und nur zusehen durfte...

Diesmal bin ich schlappe drei Jahre investiert (mit bereits abgeschriebener Kohle), sehr gut bestueckt und momentan happy.
Allerdings bin ich auch extrem skeptisch gegenueber dem Wert, da Gewinne schnell realisiert werden koennen und der Kurs danach wieder voellig absacken kann.

Kein schlecht Reden beabsichtigt, aber wieso ist das Teil immernoch ein Pink Sheet (ok - ich kenne die Hintergruende, aber ein Relisting waere wohl langsam angesagt, oder!?) Trotz sechs Jahren Boersen Erfahrung und diversen Leidenswegen, habe ich immer noch keinen Plan wie man denn so einen delisteten Wert verkauft!?

Tipps zum Thema Pink Sheets waeren klasse (nein ich will nicht verkaufen, aber ich habe auch keine Lust in der Ahnungslosigkeit rumzuduempeln...).

What ever - sollte diese Spekulation aufgehen so duerfte mehr als ein redesignter Garten drin sein.

Machs nochmal Interferon!!!

Die Spannung steigt und wir sind dabei! Ich werde am naechsten WE ein wenig Recherche betreiben und die Ergebnisse hier reinstellen...


Gruss und good luck!!

cu
POLYHAWK

[armselig]

@polyhawk
Ich habe seinerzeit ( nach dem Relisting in Deutschlad )
meine Aktien ins Depot ins Amiland transferiert.
Kostet aber 50 Eurs.
vor kurzen wurde mir gesagt ich kann jedoch auch in Deutschland gekaufte Aktien an der OTC verkaufen, wenn sie die gleichen
insi Nummern haben.
Naja nun sind sie ja drüben...
Trotzdem frage ich mich immernoch warum sie steigt..
Ohne jede Info ist es sehr schwierig den richtigen
Ausstiegspunkt abzuwägen.
Aber solange sie steigt können wir ja ruhig zuschauen und Pläne für den Garten zeichnen
Gruß

[weierHai]

HAllo IFS Gemeinde,

am 16.05.05 stand in den Unternehmensnews unten eingefügter Absatz, so daß vielleicht heute die positiven News kommen werden. Anscheinend wissen da einige schon mehr und decken sich in den letzten Tagen mit Aktine ein. Alles in allem bin ich eigentlcih sehr zuversichtlich, da Alferon im Vergleich zu den bekannten Produkten der Konkurrenz wesentlcih bessere Ergebnisse liefert..... Kurzum HEB US hat die REchte an diesem Präparat und seinen Ablegern bis zum 17.03.2006 erworben. Umsatzprov. hieraus 6,00%. Anschließend geht die Lizenz wieder an IFSC zurück.

bin wirklich positiv gestimmt , was nicht heißen soll daß starke Kursschwankungen folgen werden.

In diesem Sinne hoffe ich ein wenig Licht ins dunkel gebracht zu haben, schließlihc verfolge ich diesen Wert auch schon einige Jahre. Dfie Zeit ist meiner Ansicht nach nun reif für einen deutlcihen Kurssprung
der weiße Hai




PART III - NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 20-F, 11-K, 10-Q, or
N-SAR, or the transition report or portion thereof could not be filed within the
prescribed time period.

The registrant is unable to finalize certain information which is expected to be
available by May 20, 2005.

PART IV - OTHER INFORMATION

[1] Name and telephone number of person to contact in regard to this
notification

Lawrence M. Gordon (908) 663-2150
[Name] [Area Code] [Telephone No.]

[weierHai]

Hallo armselig,

bin von den Zahlen schon ein wenig enttäuscht, aber es gibt diverse Researchstudien von IFSC vom 22,05,05 von Morningstar, Price Target Report, und Reuters. Leider kostenpflichtig. Hat irgendjemand eine solche Studie angefordert? Wäre nett wenn Infos ins Board gestellt würden. Trotz der schwachen Zahlen bleibt der Wert stabil wenn auch bei kaum nennenswerten Umsätzen ( gestern 5800). Ich glaub da steckt merh dahinter, denn sonst würde der Wert abschmieren.
Bin gespannt welche Überraschung noch auf uns wartet.

mfg
der weiße Hai

[armselig]

Tja,
was soll man viel erwarten , die sitzen da anscheinend und ruhen sich auf ihren Lorbeeren aus und bekommen 6%.
Evtl.steht ja ein neuer Deal an für das Alphaferon oder koplette Übernahme. Jedoch was soll da übernommen werden??
Kann ja nur um das Patentportfolie gehen.
Vielleicht demnächst mal ein paar Aktien schmeißen, sid ja wenigstens grün
Gruß

[weierHai]

Hallo Armselig,

nur so als Gedankenfutter!!
Warum sollten ausgerechnet Researchstudien bie einem so unbekannten Pennystock erfolgen? Ich glaube kaum um hier eine Verkaufsempfehlung zu geben!
Ich denke da raschelt es ganz gewaltig im Gebüsch. Vielleicht hängt es auch mit der Zusammenarbeit der Gesellschaft Amphioxus Cell Technology zusammen.
der weiße Hai

[armselig]

weierHai,
hast auch wieder recht also erstmal weiter halten...
machen wir ja eh schon n paar Jahre
Gruß
armselig

[polyhawk]

@ armselig

Vielen Dank fuer den guten Tipp in Posting #147 und sorry fuer die verspaetete Antwort - bin momentan mehr als beschaeftigt.

Klar, ich bin und bleibe dabei - dennoch good to know...

Die momentane Entwicklung macht wenig Sinn - keine tollen Nachrichten, keine Uebernahme..., aber bemerkenswerte Umsaetze!


Abwarten und cool bleiben...


cu
POLYHAWK

[weierHai]

Hallo armselig,

das sehe ich anders. Fakt ist gestern gab es sehr hohe Umsätze in IFS 561000 shares. Am 16.05.05 wurde unter HEB veröffentlicht,

da*ALFERON LDO NOW IN HUMAN CLINICAL TRIALS AS EXPERIMENTAL per 16.05.2005 unter HEB US
*HEMISPHERX BEGINS TRIALS FOR ACCELERATED ALFERON LDO EVALUATION

am 03.Juni die Ankündigung über ein Shareholder Meeting
HEB schedules shareholder meeting for 22-Jun-05 10:00am ET.

Also meiner Meinung nach wissen einige schon mehr. Es sieht nach verdeckten Insiderumsätzen aus.

Bin gespannt wie die Bewertung Alferon und das Marktpotenzial aussehen werden.

bin weiterhin sehr optimistisch gestimmt.

der weiße Hai

[armselig]

@weierHai,
bin gerade aus dem Urlaub zurück.
Nun mal sehen was da folgt
bleibe gespannt und invetsiert, jedenfalls
gibt es ja anscheinen news demnächst
Gruß

[armselig]

Na ist ja zeihmlich langweilig hier.
Nun.. ich habe mal ein Posting aus dem Hemi thread kopiert.
Es steht für mich eigentliche eine Frage an , die mir hoffentlich jemand beantworten kann... aber erstmal das schon etwas alte Posting:
#60 von tilt 11.06.05 11:36:09 Beitrag Nr.: 16.865.113
Dieses Posting: versenden | melden | drucken | Antwort schreiben HEMISPHERX BIOPHARMA, INC.

Press Release Source: Hemispherx Biopharma, Inc.


Alferon LDO Now in Human Clinical Trials As Experimental Antiviral/Immunodulatory Therapy
Monday May 16, 8:30 am ET
Accelerated Evaluation of a Synergistic Cocktail of Eight Different Alpha-Interferons to Potentially Trigger " Guardian Angel" Genes


PHILADELPHIA--(BUSINESS WIRE)--May 16, 2005-- Hemispherx Biopharma, Inc. (AMEX: HEB - News) has initiated clinical trials as part of an accelerated evaluation of the experimental bio-therapeutic Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) as a potential new experimental therapy for Avian Flu and other lethal viral diseases, which have high acute death rates.
ADVERTISEMENT


Clinical trials in human volunteers (being conducted in both the U.S. at Drexel University, Philadelphia, and shortly to commence in Hong Kong at the Princess Margaret Hospital) are designed to determine whether Alferon N, delivered in a new, experimental oral drug delivery format, can resuscitate the broad-spectrum antiviral and immunostimulatory genes. These human genes are shut down by acute lethal viral infections such as avian flu and smallpox.

The Center for Disease Control and Prevention (CDC) recently announced " risky" in vitro experiments, which simulate the mixing and matching of genes between the avian flu virus, and a common human flu virus. Such `recombination` might grow into a pandemic highlighting the intense present scientific interest in this molecular biological topic.

Dr. Brian Williams a world renowned researcher at the Cleveland Clinic will be the research collaborator in the clinical trials. His research group already pioneered the identification of many of the interferon (IFN) related genes which are the subject of the present clinical investigations. In the prospective clinical tests systemic blood samples will be sampled for gene activation after brief exposure of Alferon N to the buccal (oral) mucosa of volunteers.

Immunity against viruses can typically take two forms: innate immunity and `learned` (adaptive) immunity. The NIH is currently pursuing adaptive immunity by launching nationwide vaccine testing against the avian flu. Vaccines are promising, but may have the distinct disadvantage of minimal value in individual post-viral exposure; vaccines can also become useless in the event of viral mutation (classically seen with the flu viruses and HIV/AIDS viruses).

In contrast, the innate immune system, having evolved over millennia to function within moments of encountering viruses, can prevent or ameliorate infections in animal models. Also, because innate immunity operates via immune " cascades" , i.e., multiple steps of viral blockade, mutation to resistance by the virus may be more difficult.

Hemispherx, and several other Biopharma companies, are evaluating genetic-based experimental approaches to potentially reverse the high death rate. " Guardian angel genes" is a term of art applied to critically important genes, including the IFN modulated genes, which in nature apparently can protect the human host from acute death due to overwhelming viral injection. Reconstruction experiments conducted by the CDC have pointed towards the disablement of these IFN genes as the proximate cause of death.

Nun also Hemispherx ist in der III Clinischen Phase für Alferon und testet nun an Menschen.
Wenn nun alle Rechte an Alferon ab 2006 wieder an Interferon Sciences gehen was soll das alles????
Für ein Einschätzung wäre ich dankbar
Gruß armselig

[weierHai]

Hallo armselig,

nach Ablauf der Frist im März 2006 gehen sämtliche Rechte an Alferon wieder an Interferon zurück. Sollte die Marktreife erreicht werden, wovon ich ausgehe ( gute Ergebnisse im Vergleich zu ähnlichen Konkurrenzprodukten) so besteht hier enormes Potential. Warte sehnsüchtigt auf eine Stellungnahme zum Shareholdermeeting vom 22.06.2005 von HEB. Die seit einigen Monaten steigenden Umsätze deuten meines Erachtens schon in die richtige Richtung. Vermutlich positionieren sich schon einige im Vorfeld sofern das Marktpotential ( allein als Medikament gegen die Vogelgrippe) ausgeschöpft werden kann.
Hier schlummert meines Erachtens ein riesiges Potential.

HEB muß sich also ranhalten, um die beretis gezahlten Lizenzgebühren zu erwirtschaften. Da läuft ganz sicher was im Hintergrund, vielleicht eine spätere Übernahme von Interferon durch HEB nicht ausgeschlossen um sich die Rechte langfristig zu sichern,

warten wir mal ab
bis dann
derweiße Hai

[armselig]

Hallo weierHai,
schönen Dank für deine Einschätzung.
Ich bin immer kurz vor einem Telverkauf...
aber ich halte sie wohl doch.
Ist immer nicht schön nie etwas von einer Aktie im Depot
zu hören.
So denn laßt uns mal ein wenig Glück haben
so long
armselig

[weierHai]

Hallo IFS Gemeinde,

so langsam wird`s spannend. Aber wo bleiben nur die Kommentare von Tornado? Der hat sihc seit 06/2004 hier nicht mehr blicken lassen.
Bin weiterhin zuversichtlich. Da ist irgend etwas im Busch...

der weiße Hai

[polyhawk]

@ Hai

Dieser Thread kann vieles gebrauchen, nur kein Tornado Geschwalle. Der Mac hat sich mit Posting #123 voellig negativ geoutet und selbst als ehemaliger Doofpusher deklariert.

Ich wuerde auch gerne wissen was abgeht - auf Orakel und Surfer verzichte ich allerdings gerne...

Der Trend ist unglaublich fundamental (fuer hiesige Verhaeltnisse) und relativ umsatzkraeftig. Obwohl ich ueber 400% im Plus bin, fuehle ich keinen Verkaufsanreiz. Keine Ahnung warum, aber ich war immer von den frueheren Interhypes begeistert und hoffe auf ein Replay. Bleibt das Erlebnis aus
- kein Thema die Kohle hatte ich bereits mental als Verlust abgerechnet....


Ich bleibe dabei und grins mir einen!

Gruss und good luck

cu
POLYHAWK

[armselig]

Naja, wenigstens können wir uns jetzt schon mal zu dritt
wundern was und warum da etwas abgeht
Schönen Gruß und weiterhin ein genußvolles Zurücklehnen
armselig

[weierHai]

@polyhawk

zur Zeit sind wir hier anscheinend nur zu dritt, die Interesse an IFS haben. Hat von Euchbeidne zufällig jemand einen der zahlungspflichtigen Researchstudien erworben. Über Yahoo sind in letzter Zeit etliche zahlungspflichtigen Reports zu Interferon angezeigt worden. Nun da die Vogelgrippe nun auch in Rußland angekommen zu sein scheint, und eine Übertragung des Virus via Zugvögel höchst wahrscheinlich ist, wäre vielleicht das IFS Präparat gegen die Vogelgrippe, welches in einem der vergangenen Corp.News veröffentlicht wurde ein geeignetes Mittel mit entsprechendem Absatzpotential.
Desweiteren wird anscheinend die Internetseite nue aufpoliert. Sie befindet sich schon seit einiger Zeit " under construction"
Also Augen auf und bitte um Mitteilung falls jemand was zu dem Wert an Meldungen herausfindet. Am 23,08 sollte der nächste Quartalsbericht veröffentlicht werden.

bis dann
der weiße Hai

[weierHai]

nur zur Info!

bei HEB US gab es heute einen Bericht über 70 Seiten. Unter anderem wurde sich auch auf die Alferon Produktfamilie bezogen. Ich glaub es könnte langsam spannend werden, aber die FDA Zulassung fehlt noch, Der Kurs erreichte heute ein Hoch bei 0,20 Umsatz über 226000 Aktien bei einem BID ASK Spread von 16 zu 20 wurden zu Börsenschluß 500 verkauft. Schlußkurs somit ,16. Ebenfalls merkwürdig zu Börsenbeginn wurde versucht den Kurs massiv zu drücken. Verkauf zu ,145 auch wieder nur kleine Stückzahlen. Ein Schelm wer böses dabei denkt!!

Ich werde den Eindruck nicht los das versucht wird einige Kleinanleger zu verunsicher um ihre Aktien zu verkaufen um dann wieder günstig aufzustocken.

na ja könnt ja ebenfalls mal eure Meinung dazu kundtun
gut N8
derweiße Hai

[weierHai]

Hallo IFS Gemeinde,

ich hoffe nicht das ich hier der Alleinunterhalter bleibe!
Also gestern wrude unter Hemispherx Biopharma ein Bericht veröffentlicht in dem u.a. auf die Rechte an Alferon und deren Produktfamilie eingegangen wurde. Anscheindne will dieFDA weitere Tests gemäß Mitteilung vom 30,06,05 an HEB US.
Vielleihct erfahren wir ja näheres bzgl. der Marktreife ( von der ich aus heutiger Sciht ausgeeh!) beim Quartasbericht von IFS so um den 23.08,05 herum.

bis dann
der weiße Hai

[armselig]

@weierHai
bist ja nicht ganz Alleinunterhalter
wenigsten einer der mal liest...
übrigends kann ich auf der www.hemispherx.net
Seite nicht finden
Kannst du mir mal den Link reinstellen
Schönen Dank

[weierHai]

Hallo armselig,

das geht leider nicht. Die Info hab ich in Bloomy gefunden. Dokument mit 135 Seiten. Leider nicht als File abrufbar, sonst würd ich`s gerne reinstellen.

bis dann
der weiße Hai

[armselig]

Soso,
Interferon hat jetzt 2 WKN 988946 und WKN 918064 alt

Wieso gibt es soetwas??

[Aktiensurfer]

Ich habe auch keine Erklärung.
Würde mich auch interessieren.
Wo hast du den die "neue" WKN gesehen.
Z.B. bei ARIVA.DE ist mir der neuen Nummer nichts zu finden.
Gruß
Aktiensurfer

[armselig]

@Aktiensurfer

Gehe mal auf www.consors.de und dort auf der Startseite
links die neue WKN eingeben 988946...

ansonsten habe ich auch noch nichts gefunden unter der WKN

[weierHai]

Hallo ihr beidne Mitstreiter,

hab in Bloomy ebenfalls eine neue CUSIP gefunden 458903101. Wird hier etwa eine Kapitlamaßnahme vorbereitet?
We will see. Hoffe das endlich der Quartalsbericht erscheint ( Termin bis 23.08) Um Alferon zu beurteilen verweise ich nochmal auf Hemiphex Biopharma. Dort wird entsprechend über die Zukunftsaussichten sowie das Marktumfeld informiert. Fehlt nur noch die endgültige Zulassung derFDA. Die wollte lt. Bericht HEB US noch weitere Test sehen.

bis dann
gut N8
der weiße Hai

[armselig]

Moin,

anbei etwas was ich nicht begreife ob es nun eine abgeschlossene Studie ist oder eine zu beginnende hmmm???

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

This study has been completed.

Sponsored by: Interferon Sciences
Information provided by: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier: NCT00002018


Purpose

To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.
Condition Intervention
HIV Infections
Drug: Interferon alfa-n3


MedlinePlus related topics: AIDS


Study Type: Interventional
Study Design: Treatment, Double-Blind

Eligibility

Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria

Concurrent Medication: Allowed:

Zidovudine (AZT).
Didanosine (ddI)
Patients must have:

Seropositivity to HIV-1 by ELISA and Western blot.
At least 1 of the HIV-related clinical symptoms or opportunistic infections listed in protocol.
Written informed consent.
If already on zidovudine (AZT) or didanosine (ddI), must have been on this therapy for at least 75 of the 90 days prior to study entry.
Prior Medication: Allowed:

Zidovudine (AZT).
Didanosine (ddI)
Exclusion Criteria

Co-existing Condition: Patients with the following conditions or symptoms are excluded:

Major active opportunistic infection requiring active care within 2 weeks of study entry.
Evidence of chronic hepatitis with severe liver dysfunction:
albumin < 2 g/dl and SGOT or SGPT > 5 x upper limit of normal prothrombin time > 1.5 x upper limit of normal).
Other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, neurologic, or psychiatric disorder.
Transfusion dependency defined as requiring > 1 unit of packed red blood cells (RBC) per month within 3 months prior to study entry.
Concurrent Medication: Excluded:

Experimental medications other than didanosine (ddI).
Chronic prophylactic use of any topical or systemic fungal medication such as ketoconazole, fluconazole, or clotrimazole.
Chronic prophylactic use of any topical or systemic anti-viral medication such as acyclovir or ganciclovir except zidovudine (AZT) or didanosine (ddI).
Patients with the following are excluded:

Asymptomatic at study entry.
Presence of antibodies to interferon due to prior therapy.
Hospitalization within 2 weeks of study entry.
Transfusion dependency.
Unwilling or unable to give informed consent.
Evidence of any concurrent organ dysfunction listed in Exclusion Co-Existing Conditions.
Unlikely or unable to comply with the requirements of the protocol.
Prior Medication: Excluded within 6 weeks of study entry:

Interferons.
Excluded within 45 days of study entry:
Immunosuppressive agents.
Chemotherapy.
Steroids.
Immunomodulators.
Isoprinosine.
BCG vaccine.
Prior Treatment: Excluded within 2 weeks of study entry:

Hospitalization.
Active intravenous (IV) drug abuse.

Location Information


New York
Mount Sinai Med Ctr, New York, New York, 10029, United States
More Information

Study ID Numbers: 069B; 90-355ME
Last Updated: June 30, 2005
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00002018
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-12

Quelle: http://clinicaltrials.gov/show/NCT00002018

Gruß


und gleich noch der verzögerte QB

[armselig]

Hallo nochmal,

weierHai ist es wirklich so, dass Alferon N nächstes Jahr zurückgeht, denn aus dem folgenden Bericht kann ich nicht herauslesen naja viel Spaß

IFSC.PK > SEC Filings for IFSC.PK > Form 10QSB on 20-May-2005 All Recent SEC Filings




Show all filings for INTERFERON SCIENCES INC | Request a Trial to NEW EDGAR Online Pro

Form 10QSB for INTERFERON SCIENCES INC


--------------------------------------------------------------------------------

20-May-2005

Quarterly Report



Note 2. Plan of Operations
On March 11, 2003, the Company sold all its inventory related to ALFERON N Injection and granted a license to sell the product to Hemispherx Biopharma, Inc. ("HEB"). In exchange for the inventory and license, the Company received 424,528 shares of HEB common stock with a guaranteed value of $675,000, an additional 62,500 shares of HEB common stock without a guaranteed value, and future royalties equal to 6% of the net sales of ALFERON N Injection. During 2003, the Company sold all 487,028 shares of HEB common stock and realized net proceeds of $ 1,207,000. In addition, HEB assumed approximately $408,000 of the Company`s payables and various other commitments. On March 11, 2003, the Company and HEB entered into another agreement, which was consummated on March 17, 2004, pursuant to which the Company sold to HEB, the Company`s real estate property, plant, equipment, furniture and fixtures, rights to ALFERON N Injection and all of its patents, trademarks and other intellectual property related to its natural alpha interferon business. In exchange, the Company received 424,528 shares of HEB common stock with a guaranteed value of $675,000, an additional 62,500 shares of HEB common stock without a guaranteed value and future royalties equal to 6% of the net sales of all products sold containing natural alpha interferon. During 2004, the Company sold all 487,028 shares of HEB common stock and realized net proceeds of $1,936,000. In addition, approximately $2.5 million of the Company`s indebtedness which encumbered its assets was repaid by HEB. Prior to the completion of this transaction, HEB funded certain operating costs of the Company`s facility such as insurance, heat, light, air conditioning and equipment maintenance (See Note 7).

Currently, ISI`s sole activity is completing the acquisition of Amphioxus Cell Technologies ("ACT"). ACT and ISI have entered into a non-binding Letter of Intent, which is described in Note 8.

At March 31, 2005, the Company had approximately $ 1,508,000 of cash and cash equivalents, with which to support future operating activities and to satisfy its financial obligations as they become payable.

The Company has experienced significant operating losses since its inception. As of March 31, 2005, the Company had an accumulated deficit of approximately $136.5 million. For the three months ended March 31, 2005, the Company incurred a net loss of $0.2 million. For the years ended December 31, 2004 and 2003, the Company had net income of approximately $ 1.7 million and $2.3 million, respectively, from the sale of its assets. Based on the Company`s current cash position, estimates of revenues, expenses, and the timing of repayment of creditors, management believes that the Company has sufficient resources to enable it to continue activities through March 31, 2006. However, actual results may differ materially from such estimate, and no assurance can be given that additional funding will not be required sooner than anticipated or that such additional funding, whether from financial markets or from other sources, will be available when needed or on terms acceptable to the Company. Insufficient funds will require the Company to curtail or terminate its activities.

Note 3. Earnings (Loss) Per Share

Basic earnings (loss) per share have been computed using the weighted average number of shares of common stock of the Company outstanding for each period presented. For the three months ended March 31, 2004, the dilutive effect of stock options and other common stock equivalents is included in the calculation of diluted earnings per share using the treasury stock method. For the three months ended March 31, 2005, common stock equivalents are not included in the calculation of loss per share as the effect would be antidilutive.

Note 4. Agreement with GP Strategies Corporation

Pursuant to an agreement dated March 25, 1999, GP Strategies Corporation ("GP Strategies") loaned the Company $500,000 (the "GP Strategies Debt"). In return, the Company granted GP Strategies (i) a first mortgage on the Company`s real estate, (ii) a two-year option (which has expired) to purchase the Company`s real estate, provided that the Company has terminated its operations and a certain liability to the American Red Cross (the "Red Cross") has been repaid, and (iii) a two-year right of first refusal (which has expired) in the event the Company desires to sell its real estate. In addition, the Company issued GP Strategies 500,000 shares (the "GP Shares") of common stock and five-year warrant (the "GP Warrant") to purchase 500,000 shares of common stock at a price of $1 per share. Pursuant to the agreement, the Company has issued a note to GP Strategies representing the GP Strategies Debt, which note was originally due on September 30, 1999 (but extended to June 30, 2001) and bore interest, payable at maturity, at the rate of 6% per annum. In addition, at that time, the Company negotiated a subordination agreement with the Red Cross pursuant to which the Red Cross agreed that its lien on the Company`s real estate is subordinate to GP Strategies` lien. On March 27, 2000, the Company and GP Strategies entered into an agreement pursuant to which (i) the GP Strategies Debt was extended until June 30, 2001 and (ii) the Management Agreement between the Company and GP Strategies was terminated and all intercompany accounts between the Company and GP Strategies (other than the GP Strategies Debt) in the amount of approximately $130,000 were discharged which was recorded as a credit to capital in excess of par value. On August 23, 2001, the Company and GP Strategies entered into an agreement pursuant to which the GP Strategies Debt was extended to March 15, 2002. During 2001, the Company paid GP Strategies $100,000 to reduce the GP Strategies Debt. In addition, in January 2002, the Company paid GP Strategies $100,000 to further reduce the GP Strategies Debt. In connection with the Asset Sale Transactions (as hereafter defined, see Note 7), the Company, HEB and GP Strategies entered into an agreement pursuant to which GP Strategies agreed to forbear from exercising its rights until May 31, 2003 and GP Strategies agreed to accept HEB common stock with a guaranteed value of $425,000 in full settlement of all the Company`s obligations to GP Strategies. On June 2, 2003, HEB delivered the HEB common stock to GP Strategies in accordance with HEB`s obligation under the terms of the forbearance agreement. However the forbearance agreement provided that in addition to the issuance by HEB of the HEB common stock to GP Strategies, HEB was obligated to register the HEB common stock for resale and any shares of HEB shares received by GP Strategies which remain unsold after November 30, 2004 may be put to HEB at a price of $ 1.59 per share.

The GP Strategies obligations were legally extinguished by HEB on June 2, 2003. The Asset Sale Transaction with HEB closed on March 17, 2004. If the transaction had not closed, HEB would have had a claim against ISI for the satisfaction of the GP Strategies obligations. For accounting purposes, these transactions were treated as integral parts of the Asset Sale Transactions and accordingly, the obligations remained on the balance sheet until the closing of the transaction on March 17, 2004, at which time the amount of such obligations were recognized as extinguished for accounting purposes.

Note 5. Agreement with the Red Cross

The Company obtained human white blood cells used in the manufacture of ALFERON N Injection from several sources, including the Red Cross pursuant to a supply agreement dated April 1, 1997 (the "Supply Agreement"). As of November 23, 1998, the Company owed the Red Cross approximately $1.46 million plus interest at the rate of 6% per annum accruing from April 1, 1998 (the "Red Cross Liability") for white blood cells purchased pursuant to the Supply Agreement.

Pursuant to an agreement dated November 23, 1998, the Company granted the Red Cross a security interest in certain assets to secure the Red Cross Liability, issued to the Red Cross 300,000 shares of common stock and agreed to issue additional shares at some future date as requested by the Red Cross to satisfy any remaining amount of the Red Cross Liability. The Red Cross agreed that any net proceeds received by it upon sale of such shares would be applied against the Red Cross Liability. In January 1999, the Company granted the Red Cross a security interest (the "Security Interest") in, among other things, the Company`s real estate, equipment inventory, receivables, and New Jersey net operating loss carryovers to secure repayment of the Red Cross Liability, and the Red Cross agreed to forbear from exercising its rights under the Supply Agreement, including with respect to collecting the Red Cross Liability until June 30, 1999 (which was subsequently extended until December 31, 1999). On December 29, 1999, the Company, the Red Cross and GP Strategies entered in an agreement pursuant to which the Red Cross agreed that until September 30, 2000 it would forbear from exercising its rights under (i) the Supply Agreement, including with respect to collecting the Red Cross Liability, and (ii) the Security Interest. In connection with the Asset Sale Transactions (see Note 7), the Company, HEB and the Red Cross entered into an agreement pursuant to which the Red Cross agreed to forbear from exercising its rights until May 31, 2003 and the Red Cross agreed to accept HEB common stock with a guaranteed value of $500,000 in full settlement of all of the Company`s obligations to the Red Cross. On June 2, 2003, HEB delivered the HEB common stock to the Red Cross in accordance with HEB`s obligation under the terms of the forbearance agreement. However the forbearance agreement provided that in addition to the issuance by HEB of the HEB common stock to the Red Cross, HEB was obligated to register the HEB common stock for resale and any shares of HEB shares received by the Red Cross which remain unsold after May 31, 2004 may be put to HEB at a price of $ 1.59 per share.

The Red Cross Liability was legally extinguished by HEB on June 2, 2003. The Asset Sale Transaction with HEB closed on March 17, 2004. If the transaction had not closed, HEB would have had a claim against ISI for the satisfaction of the Red Cross Liability. For accounting purposes, these transactions were treated as integral parts of the Asset Sale Transactions and accordingly, the obligations remained on the balance sheet until the closing of the transaction on March 17, 2004, at which time the amount of such obligations were recognized as extinguished for accounting purposes.

Note 6. Recently Issued Accounting Standards

In December 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), "Share-Based Payment" (SFAS 123R), which replaces SFAS No. 123, "Accounting for Stock-Based Compensation," (SFAS 123) and supercedes APB Opinion No. 25, "Accounting for Stock Issued to Employees." SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values beginning with the first interim or annual period after June 15, 2005, with early adoption encouraged. The pro forma disclosures previously permitted under SFAS 123 no longer will be an alternative to financial statement recognition. The Company is required to adopt SFAS 123R beginning July 1, 2005. Under SFAS 123R, the Company must determine the appropriate fair value model to be used for valuing share-based payments, the amortization method for compensation cost and the transition method to be used at date of adoption. The transition methods include prospective and retroactive adoption options. The Company has begun, but has not completed, evaluating the impact of the adoption of SFAS 123R on its results of operations. In connection with evaluating the impact of SFAS 123R, the Company is considering the potential implementation of different valuation methods to determine the fair value of share-based compensation. The Company believes the adoption of SFAS 123R will have a material impact on its results of operations, regardless of the valuation method used. Currently, the Company does not have any employee stock options outstanding.

Note 7. Agreement with Hemispherx Biopharma, Inc. ("HEB")

On March 11, 2003, the Company executed two agreements with HEB to sell certain assets of the Company (the two asset sale transactions are hereinafter jointly referred to as the "Asset Sale Transactions" and individually referred to as the "First Asset Sale" and the "Second Asset Sale") and consummated the First Asset Sale.

In the first agreement with HEB (the "First Asset Sale Agreement"), the Company sold all of its inventory related to ALFERON N Injection(R) (the "Product") and granted a three-year license for the production, manufacture, use, marketing and sale of the Product in the United States.

For these assets, the Company:

(i) received 424,528 shares of HEB common stock (the "HEB Common Stock") which had a Guaranteed Value (as defined in the First Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without a Guaranteed Value; and

(iii) will receive a royalty equal to 6% of the net sales of the Product.

In addition, HEB assumed $408,000 of ISI payables and certain other obligations related to the Product. The consummation of the First Asset Sale Agreement resulted in a gain of $1,149,112, which is included in the consolidated statement of operations for the year ended December 31, 2003.

ISI received a service fee until October 31, 2003 for providing certain transitional services. Such service fee was $560,101 for the year ended December 31, 2003. As of December 31, 2003, the Company sold all 487,028 shares of HEB Common Stock and realized net proceeds of $1,207,000, resulting in a gain of $ 447,337, which is included in the consolidated statement of operations for the year ended December 31, 2003.

In the second agreement with the Company (the "Second Asset Sale Agreement"), which was consummated on March 17, 2004, the Company sold to HEB all of its rights to the Product and other assets related to the natural alpha interferon business including, but not limited to, real estate, machinery and equipment. For these assets, the Company:

(i) received 424,528 shares of HEB Common Stock which has a Guaranteed Value (as defined in the Second Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without a Guaranteed Value; and

(iii)will receive a royalty equal to 6% of the net sales of any products containing natural alpha interferon sold by HEB (or a Marketing Partner, as defined in the Second Asset Sale Agreement).

In addition, HEB satisfied the Company`s obligations to (i) the American Red Cross in the amount of $1,435,000, (ii) GP Strategies Corp. in the amount of $423,000, and (iii) MD Sass in the amount of $644,000 (for unpaid local property taxes and water and sewer charges). The consummation of the Second Asset Sale Agreement resulted in a gain of $2,875,282, which is included in the consolidated condensed statement of operations for the quarter ended March 31, 2004. Through March 31, 2004, no shares received from the Second Asset Sale Agreement were sold. As of December 31, 2004, the Company sold all of the shares of HEB common stock and realized net proceeds of $1,935,683, resulting in a gain on the sale of the HEB common stock of $270,048.

Note 8. Note Receivable - Agreement with Amphioxus Cell Technologies, Inc.
("Amphioxus")

On March 20, 2003, the Company entered into a collaterialized note agreement, as amended (the "Note") with Amphioxus to advance up to $500,000. Pursuant to the Note, the Company advanced $375,000 as of December 31, 2003. In October 2004, the Company advanced an additional $100,000. The Note is due on June 30, 2005, bears interest at the rate of 10% per annum and is collaterialized by all of the assets of Amphioxus. In addition, the Company received a warrant, exercisable until March 2008, to purchase for $100,000, an aggregate of 20% of the common stock of Amphioxus on a fully diluted basis. The warrant is valued at $15,000, and such value is prorated based on the amount of monies advanced and was amortized as interest income over the original term of the Note.

On October 17, 2003, ISI and ACT entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT.

The Letter of Intent is subject to the execution of definitive documents and final due diligence. There can be no assurance that a definitive agreement will be consummated.

At December 31, 2004, the Company set up a provision against the collectibility of the note and related interest due from ACT, due to the uncertainty of the collectibility of such note and interest and to reflect its estimated fair value. In addition, at March 31, 2005, the Company wrote off the carrying value of the ACT warrant.

Note 9. Notes Payable

In August 2002, the Company completed a private placement of $500,000 of convertible notes to accredited investors. Each note is convertible into the Company`s common stock at a price of $.05 per share (subject to adjustment to 70% of the market price of the Company`s common stock under certain circumstances) and bears interest at the rate of 10% per annum. A $250,000 convertible note was due January 31, 2003 and the other $250,000 of the convertible notes were due December 31, 2003. For each $100,000 principal amount of notes issued, the investors received warrants to purchase an additional 10.2 million shares of the Company`s common stock exercisable at $.01 per share. The warrants were valued at $400,000 and are amortized as interest expense over the terms of the respective notes. The conversion of the convertible notes and the exercise of the warrants are subject to approval by the shareholders of the Company of the availability of a sufficient number of authorized common shares. The terms of the notes, as amended, include the Company obtaining stockholder approval by June 30, 2005 to increase its authorized shares so that the number of authorized but unissued common shares is at least 200% of the number of common shares issuable on conversion of the notes and exercise of the warrants. Failure to obtain stockholder approval for the increase in the authorized number of shares and to file with the Delaware Secretary of State an amendment to the Company`s Certificate of Incorporation, on or before June 30, 2005 to increase its authorized shares, would require the Company to make cash payments to each warrant holder, for each 30-day period such approval has not been obtained, equal to the difference between the exercise price and volume weighted average market price (for that 30-day period) for all warrants not exercisable because of the failure to obtain the approval. Further the note holders have registration rights whereby, for the period commencing April 30, 2004 but no later than August 7, 2005, upon written request from at least 50% of the holders of the shares issuable upon the exercise of the warrants, the Company is to file a registration statement within 30 days and have such registration statement declared effective 90 days thereafter, to register the common shares underlying the convertible notes and warrants. The Company`s failure to file a registration statement or have one declared effective by the required dates would result in the Company paying liquidated damages to each of the above note-holders in an amount equal to 2% of the outstanding principal amount of the convertible notes per month for each 30 day period or part thereof, a registration statement was not filed. In addition, these notes are convertible into common stock at a beneficial rate. The beneficial conversion feature was valued at $100,000 and accounted for as debt discount and was amortized over the term of the notes. The $250,000 note due on January 31, 2003 was repaid in full (including accrued interest) in November 2003. Of the $250,000 notes which were due December 31, 2003, $ 25,000 was repaid (including accrued interest) in May, 2004 and the remaining $ 225,000 are still unpaid.


INTERFERON SCIENCES, INC. AND SUBSIDIARY

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
ISI was incorporated in 1980 and until March 11, 2003, ISI was a biopharmaceutical company which studied, manufactured, and sold ALFERON N Injection(R), a highly purified, multi-species, natural-source alpha interferon product (the "Product"). ALFERON N Injection is approved by the FDA for the treatment of certain types of genital warts and has been studied for its potential use in the treatment of human immunodeficiency virus ("HIV"), hepatitis C virus ("HCV"), and certain other indications. ISI has experienced significant operating losses since its inception.

On March 11, 2003, ISI executed two agreements with HEB to sell certain assets of ISI. In the First Asset Sale Agreement, ISI sold all of its inventory related to ALFERON N Injection(R), ISI`s natural alpha interferon product approved for the treatment of certain types of genital warts (the "Product"), and granted a limited license for the production, manufacture, use, marketing and sale of the Product in the United States. In the Second Asset Sale Agreement, which was consummated on March 17, 2004, ISI sold to HEB all of its rights to the Product and other assets related to the Product including, but not limited to, real estate, machinery and equipment.

On October 17, 2003, ISI and Amphioxus Cell Technologies, Inc. ("ACT") entered into a non-binding letter of intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire ACT. ACT is a biotechnology company that applies liver biology solutions to problems in drug discovery and human therapeutics. The letter of intent is subject to the execution of definitive documents and final due diligence. (See Note 8).

Liquidity and Capital Resources

For the assets transferred to HEB pursuant to the First Asset Sale Agreement, ISI received 487,028 shares of HEB common stock and a royalty equal to 6% of the net sales of the Product. As of December 31, 2003, ISI sold all 487,028 shares of HEB common stock and realized net proceeds of $1,207,000. In addition, until October 31, 2003, ISI received a service fee for providing certain transitional services to HEB and HEB assumed $408,000 of ISI payables and certain other obligations related to the Product.

For the assets transferred to HEB pursuant to the Second Asset Sale Agreement, which was consummated on March 17, 2004, ISI received an additional 487,028 shares of HEB Common Stock. As of December 31, 2004, ISI sold all of the 487,028 shares of HEB common stock and realized net proceeds of approximately $ 1,936,000. In addition, HEB satisfied certain obligations relating to the real estate, machinery and equipment of ISI which aggregated approximately $2,500,000.

At March 31, 2005, the Company had approximately $ 1,508,000 in cash and cash equivalents. Until utilized, such cash and cash equivalents are being invested principally in short-term interest-bearing investments.

Based on the Company`s estimates of revenues, expenses, and the timing of repayment of creditors, management believes that the cash presently available will be sufficient to enable the Company to continue its activities through March 31, 2006. However, actual results may differ materially from such estimate, and no assurance can be given that additional funding will not be required sooner than anticipated or that such additional funding will be available when needed or on terms acceptable to the Company. Insufficient funds will require the Company to curtail or terminate its activities.

The Company`s Common Stock is traded in the over-the-counter market and quoted on the Pink Sheets, which may have a material adverse effect on the liquidity of its Common Stock and on its ability to obtain additional financing.

Results of Operations

Three Months Ended March 31, 2005 Versus Three Months Ended March 31, 2004

For the three months ended March 31, 2005 and 2004, the Company recorded royalty income from HEB of $16,000 and $14,740, respectively.

General and administrative expenses for the three months ended March 31, 2005 were $256,678 as compared to $273,394 for the same period in 2004. The decrease of $16,716 was due principally to decreases in depreciation expense and property taxes partially offset by increases in certain other operating expenses and the write off of the carrying value of the ACT warrant.

Interest income (expense), net, for the three months ended March 31, 2005 was income of $536 as compared to $6,890 for the three months ended March 31, 2004.

For the three months ended March 31, 2004, the Company recorded a gain on the sale of assets to HEB of $2,875,282.

For the three months ended March 31, 2004, the Company recorded $ 52,470 of income tax expense based upon the alternative minimum tax for federal tax purposes.

As a result of the foregoing, the Company incurred a net loss of $240,142 and earned net income of $2,571,048 for the three months ended March 31, 2005 and 2004, respectively.

Forward-Looking Statements

This report contains certain forward-looking statements reflecting management`s current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the risk that the Company will run out of cash and the uncertainty of obtaining additional funding for the Company, all of which are difficult to predict and many of which are beyond the control of the Company.


INTERFERON SCIENCES, INC. AND SUBSIDIARY

Quelle:http://biz.yahoo.com/e/050520/ifsc.pk10qsb.html

[armselig]

Hallo nochmal den Passus den ich meine, der alle Rechte an Alferon N an Hemixpherx abtritt

Note 2. Plan of Operations

On March 11, 2003, the Company sold all its inventory related to ALFERON N
Injection and granted a license to sell the product to Hemispherx Biopharma,
Inc. ("HEB"). In exchange for the inventory and license, the Company received
424,528 shares of HEB common stock with a guaranteed value of $675,000, an
additional 62,500 shares of HEB common stock without a guaranteed value, and
future royalties equal to 6% of the net sales of ALFERON N Injection. During
2003, the Company sold all 487,028 shares of HEB common stock and realized net
proceeds of $ 1,207,000. In addition, HEB assumed approximately $408,000 of the
Company`s payables and various other commitments. On March 11, 2003, the Company
and HEB entered into another agreement, which was consummated on March 17, 2004,
pursuant to which the Company sold to HEB, the Company`s real estate property,
plant, equipment, furniture and fixtures, rights to ALFERON N Injection and all
of its patents , trademarks and other intellectual property related to its
natural alpha interferon business. In exchange, the Company received 424,528
shares of HEB common stock with a guaranteed value of $675,000, an additional
62,500 shares of HEB common stock without a guaranteed value and future
royalties equal to 6% of the net sales of all products sold containing natural
alpha interferon. During 2004, the Company sold all 487,028 shares of HEB common
stock and realized net proceeds of $1,936,000. In addition, approximately $2.5
million of the Company`s indebtedness which encumbered its assets was repaid by
HEB. Prior to the completion of this transaction, HEB funded certain operating
costs of the Company`s facility such as insurance, heat, light, air conditioning
and equipment maintenance (See Note 7).

Hier schwarz makiert... nun ist das Patent wech ???

[armselig]

Hallo,
die neuen filings sind raus.
Habe ich das richtig verstanden?
Kein Alferon mehr kein HEB mehr keine Aktien von denen.
Neue Aquisition von:
Amphioxus Cell Technologies, Inc. (" ACT" )
aber nur ein letter of intend ??
ca.17.000 USD Einnahmen von Alferon

Und im Abschluß schreiben Sie ISI war eine Biotech firma ?????

Anscheinend werden nur noch die eigenen Aktien verwaltet
Und...
Steht da nicht noch was von einer Ausgabe neuer Aktien???
Sehr undurchsichtig.....
Den einzigen Gedanken den ich habe ist :
Was rechtfertig den Kursanstieg ???
Doch nicht die Aussichten dass die Firma genug Geld erachtet für ein weiteres Jahr??
Oder wird der Kurs hochgetragen um ein höheren Kurs für die neuen Aktien zu bekommen???
Schönen Gruß
das Fragezeichen


INTERFERON SCIENCES INC: 10QSB, Sub-Doc 1 BACK PRINT THIS PAGE CLOSE WINDOW


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q/SB

[x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

For the quarter ended June 30, 2005

or

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934

For the transition period from ___________ to ________________

Commission File Number: 0-10379


INTERFERON SCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)


Delaware 22-2313648
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)


1812 Front Street, Scotch Plains, New Jersey 07076
(Address of principal executive offices) (Zip code)


[phone]
(Registrant`s telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period) that the registrant was
required to file such reports and (2) has been subject to such filing
requirements for the past 90 days.

Yes [X] No [ ]


Number of shares outstanding of each of issuer`s classes of common stock as of
August 1, 2005.

Common Stock 37,339,286 shares











INTERFERON SCIENCES, INC. AND SUBSIDIARY

TABLE OF CONTENTS



Page

Part I. Financial Information:

Consolidated Condensed Balance Sheets--
June 30, 2005 and December 31, 2004. . . . . . . . . . . . . . . . . . .1

Consolidated Condensed Statements of Operations--
Three Months and Six Months Ended June 30, 2005 and 2004 . . . . . . .2-3

Consolidated Condensed Statement of Stockholders` Equity
-- Six Months Ended June 30, 2005 . . . . . . . . . . . . . . . . . . . .4

Consolidated Condensed Statements of Cash Flows--
Six Months Ended June 30, 2005 and 2004. . . . . . . . . . . . . . . . .5

Notes to Consolidated Condensed Financial Statements. . . . . . . . . .6-11

Management`s Discussion and Analysis of Financial
Condition and Results of Operations . . . . . . . . . . . . . . . .12-13

Part II. Other Information . . . . . . . . . . . . . . . . . . . . .. . . .14

Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . 15

Certifications . . . . . . . . . . . . . . . . . . . . . . . . . . . .. .16-17










INTERFERON SCIENCES, INC. AND SUBSIDIARY
PART I. FINANCIAL INFORMATION

CONSOLIDATED CONDENSED BALANCE SHEETS

June 30, December 31,
2005 2004
(Unaudited)
ASSETS ------------------------------
Current assets

Cash and cash equivalents $ 1,311,902 $ 1,888,386
Other receivables 67,962 -
Prepaid expenses and other current assets 28,586 12,531
------------- -------------
Total current assets 1,408,450 1,900,917


Other assets 1,884 16,134
------------- -------------
Total assets $ 1,410,334 $ 1,917,051
============= =============

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities
Accounts payable and accrued expenses 611,057 580,337
Convertible notes payable -past due 225,000 225,000
Income tax payable - 47,000
------------- -------------
Total current liabilities 836,057 852,337
------------- -------------
Commitments and contingencies

Stockholders` Equity
Preferred stock, par value $.01 per share;
authorized-5,000,000 shares; none issued
and outstanding
Common stock, par value $.01 per share;
authorized-55,000,000 shares; issued
and outstanding-37,339,286 shares 373,393 373,393
Capital in excess of par value 137,231,987 136,970,283
Accumulated deficit (137,031,103) (136,278,962)
------------- ------------
Total stockholders` equity 574,277 1,064,714
------------- ------------
Total liabilities and stockholders` equity $ 1,410,334 $ 1,917,051
============= =============

The accompanying notes are an integral part of these consolidated condensed
financial statements.









INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended
June 30,
-----------------------------
2005 2004
------------- -------------
Revenue

Royalty income $ 14,298 $ 17,068
------------- -------------
Total revenue 14,298 17,068
------------- -------------
Costs and expenses
General and administrative 526,453 196,469
------------- -------------
Total costs and expenses 526,453 196,469
------------- -------------
Loss from operations before
other income (expense) (512,155) (179,401)

Interest income (expense), net 156 2,479
Gain on sale of securities - 270,048
------------- -------------
Net(loss) Income $ (511,999) $ 93,126
============= =============

Basic net (loss) income per share $ (.01) $ -
============= =============

Diluted net (loss) income per share (potential
common shares limited to authorized shares
available)
$ (.01) $ -
============= =============

As adjusted, diluted net (loss) income per share
(potential common shares not limited to
authorized shares available) $ (.01) $ -
============= =============
Weighted average number of shares
outstanding - basic 37,339,286 37,339,286
============= ==============
Weighted average number of shares outstanding -
diluted (potential common shares limited to
authorized shares available) 37,339,286 55,000,000
============== ==============
As adjusted, weighted average number of shares outstanding - diluted (potential
common shares not limited to authorized shares available)
37,339,286 90,139,286
============= =============


The accompanying notes are an integral part of these consolidated condensed
financial statements.






INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

Six Months Ended
June 30,
-----------------------------
2005 2004
------------- -------------
Revenue

Royalty income $ 30,298 $ 31,808
------------- -------------
Total revenue 30,298 31,808
------------- -------------
Costs and expenses
General and administrative 783,131 469,863
------------- -------------
Total costs and expenses 783,131 469,863
------------- -------------
Loss from operations before
other income (expense) (752,833) (438,055)

Interest income (expense), net 692 9,369
Gain on sale of assets - 2,875,282
Gain on sale of securities - 270,048
------------- -------------
Income (loss) before taxes (752,141) 2,716,644
Provision for income taxes - 52,470
------------- -------------
Net(loss) Income $ (752,141) $ 2,664,174
============= =============

Basic net (loss) income per share $ (.02) $ .07
============= =============

Diluted net (loss) income per share (potential
common shares limited to authorized shares
available)
$ (.02) $ .05
============= =============

As adjusted, diluted net (loss) income per share
(potential common shares not limited to
authorized shares available) $ (.02) $ .03
============= =============
Weighted average number of shares
outstanding - basic 37,339,286 37,339,286
============= ==============
Weighted average number of shares outstanding -
diluted (potential common shares limited to
authorized shares available) 37,339,286 55,000,000
============== ==============
As adjusted, weighted average number of shares
outstanding - diluted (potential common shares
not limited to authorized shares available) 37,339,286 90,139,286
============= =============


The accompanying notes are an integral part of these consolidated condensed
financial statements.









INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED CONDENSED STATEMENT
OF STOCKHOLDERS` EQUITY
SIX MONTHS ENDED JUNE 30, 2005
(Unaudited)



Capital Total
Common Stock in excess Accumulated Stockholders`
Shares Amount of par value deficit Equity
------------------ ------------ ------------- -------------
Balance at

Dec. 31, 2004 37,339,286 $373,393 $136,970,283 $(136,278,962) $ 1,064,714

Common Stock issued
by principal stockholder
in settlement of anti-
dilution provision of
warrants 261,704 261,704

Net loss (752,141) (752,141)
------------------------------------------------------------------------------
Balance at
June 30, 2005 37,339,286 $373,393 $137,231,987 $(137,031,103) $ 574,277
==============================================================================




The accompanying notes are an integral part of these consolidated condensed
financial statements.











INTERFERON SCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

Six Months Ended
June 30,
--------------------------
2005 2004
---- ----

Cash flows from operating activities:

Net (loss) income $ (752,141) $ 2,664,174
Adjustments to reconcile net (loss) income
to net cash used for operating activities:
Write off of ACT warrant 14,250
Antidilution settlement charge 310,305
Gain on sale of assets (2,875,282)
Gain on sale of securities (270,048)
Depreciation and amortization 87,156
Amortization of interest income (3,937)
Change in operating assets and liabilities:
Other receivables (67,962) (3,750)
Prepaid expenses and other current assets (16,055) (23,939)
Accounts payable and accrued expenses (64,881) 38,454
------------ ------------
Net cash used in operating activities (576,484) (387,172)
------------ ------------
Cash flows from investing activities:
Proceeds from sale of investment 1,935,683
------------ ------------
Net cash provided by investing
activities - 1,935,683
------------ ------------
Cash flows from financing activities:
Repayment of convertible notes payable (60,000)
------------ -------------

Net cash used for financing activities - (60,000)


------------ -------------
Net (decrease) increase in cash and cash equivalents (576,484) 1,488,511

Cash and cash equivalents at beginning of period 1,888,386 848,573
------------ --------------
Cash and cash equivalents at end of period $ 1,311,902 $ 2,337,084
============ ==============

Supplemental disclosure:
Income taxes paid $ 94,750 -

The accompanying notes are an integral part of these consolidated condensed
financial statements.







INTERFERON SCIENCES, INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited)

Note 1. Basis of Presentation

The financial information included herein is unaudited. Such information,
however, reflects all adjustments (consisting solely of normal recurring
adjustments) that are, in the opinion of management, necessary for a fair
presentation of the financial position and operating results for the interim
periods. The operating results for interim periods are not necessarily
indicative of operating results to be expected for the year.

Note 2. Plan of Operations

On March 11, 2003, the Company sold all its inventory related to ALFERON
N Injection and granted a license to sell the product to Hemispherx Biopharma,
Inc. ("HEB"). In exchange for the inventory and license, the Company received
424,528 shares of HEB common stock with a guaranteed value of $675,000, an
additional 62,500 shares of HEB common stock without a guaranteed value, and
future royalties equal to 6% of the net sales of ALFERON N Injection. During
2003, the Company sold all 487,028 shares of HEB common stock and realized net
proceeds of $ 1,207,000. In addition, HEB assumed approximately $408,000 of the
Company`s payables and various other commitments. On March 11, 2003, the Company
and HEB entered into another agreement, which was consummated on March 17, 2004,
pursuant to which the Company sold to HEB, the Company`s real estate property,
plant, equipment, furniture and fixtures, rights to ALFERON N Injection and all
of its patents, trademarks and other intellectual property related to its
natural alpha interferon business. In exchange, the Company received 424,528
shares of HEB common stock with a guaranteed value of $675,000, an additional
62,500 shares of HEB common stock without a guaranteed value and future
royalties equal to 6% of the net sales of all products sold containing natural
alpha interferon. During 2004, the Company sold all 487,028 shares of HEB common
stock and realized net proceeds of $1,936,000. In addition, approximately $2.5
million of the Company`s indebtedness which encumbered its assets was repaid by
HEB. Prior to the completion of this transaction, HEB funded certain operating
costs of the Company`s facility such as insurance, heat, light, air conditioning
and equipment maintenance (See Note 7).

Currently, ISI`s sole activity is completing the acquisition of Amphioxus
Cell Technologies ("ACT"). ACT and ISI have entered into a non-binding Letter of
Intent, which is described in Note 8.


At June 30, 2005, the Company had approximately $ 1,312,000 of cash and
cash equivalents, with which to support future operating activities and to
satisfy its financial obligations as they become payable.

The Company has experienced significant operating losses since its
inception. As of June 30, 2005, the Company had an accumulated deficit of
approximately $137 million. For the six months ended June 30, 2005, the Company
incurred a net loss of approximately $0.8 million. For the years ended December
31, 2004 and 2003, the Company had net income of approximately $ 1.7 million and
$2.3 million, respectively, from the sale of its assets. Based on the Company`s
current cash position, estimates of revenues, expenses, and the timing of
repayment of creditors, management believes that the Company has sufficient
resources to enable it to continue activities through June 30, 2006. However,
actual results may differ materially from such estimate, and no assurance can be
given that additional funding will not be required sooner than anticipated or
that such additional funding, whether from financial markets or from other
sources, will be available when needed or on terms acceptable to the Company.
Insufficient funds will require the Company to curtail or terminate its
activities.




Note 3. Earnings (Loss) Per Share

Basic earnings (loss) per share have been computed using the weighted
average number of shares of common stock of the Company outstanding for each
period presented. For the three months and six months ended June 30, 2004, the
dilutive effect of stock options and other common stock equivalents is included
in the calculation of diluted earnings per share using the treasury stock
method. For the three months and six months ended June 30, 2005, common stock
equivalents are not included in the calculation of loss per share as the effect
would be antidilutive.


Note 4. Agreement with GP Strategies Corporation

Pursuant to an agreement dated March 25, 1999, GP Strategies
Corporation ("GP Strategies") loaned the Company $500,000 (the "GP Strategies
Debt"). In return, the Company granted GP Strategies (i) a first mortgage on the
Company`s real estate, (ii) a two-year option (which has expired) to purchase
the Company`s real estate, provided that the Company has terminated its
operations and a certain liability to the American Red Cross (the "Red Cross")
has been repaid, and (iii) a two-year right of first refusal (which has expired)
in the event the Company desires to sell its real estate. In addition, the
Company issued GP Strategies 500,000 shares (the "GP Shares") of common stock
and five-year warrant (the "GP Warrant") to purchase 500,000 shares of common
stock at a price of $1 per share. Pursuant to the agreement, the Company has
issued a note to GP Strategies representing the GP Strategies Debt, which note
was originally due on September 30, 1999 (but extended to June 30, 2001) and
bore interest, payable at maturity, at the rate of 6% per annum. In addition, at
that time, the Company negotiated a subordination agreement with the Red Cross
pursuant to which the Red Cross agreed that its lien on the Company`s real
estate is subordinate to GP Strategies` lien. On March 27, 2000, the Company and
GP Strategies entered into an agreement pursuant to which (i) the GP Strategies
Debt was extended until June 30, 2001 and (ii) the Management Agreement between
the Company and GP Strategies was terminated and all intercompany accounts
between the Company and GP Strategies (other than the GP Strategies Debt) in the
amount of approximately $130,000 were discharged which was recorded as a credit
to capital in excess of par value. On August 23, 2001, the Company and GP
Strategies entered into an agreement pursuant to which the GP Strategies Debt
was extended to March 15, 2002. During 2001, the Company paid GP Strategies
$100,000 to reduce the GP Strategies Debt. In addition, in January 2002, the
Company paid GP Strategies $100,000 to further reduce the GP Strategies Debt. In
connection with the Asset Sale Transactions (as hereafter defined, see Note 7),
the Company, HEB and GP Strategies entered into an agreement pursuant to which
GP Strategies agreed to forbear from exercising its rights until May 31, 2003
and GP Strategies agreed to accept HEB common stock with a guaranteed value of
$425,000 in full settlement of all the Company`s obligations to GP Strategies.
On June 2, 2003, HEB delivered the HEB common stock to GP Strategies in
accordance with HEB`s obligation under the terms of the forbearance agreement.
However the forbearance agreement provided that in addition to the issuance by
HEB of the HEB common stock to GP Strategies, HEB was obligated to register the
HEB common stock for resale and any shares of HEB shares received by GP
Strategies which remain unsold after November 30, 2004 may be put to HEB at a
price of $ 1.59 per share.

The GP Strategies obligations were legally extinguished by HEB on June
2, 2003. The Asset Sale Transaction with HEB closed on March 17, 2004. If the
transaction had not closed, HEB would have had a claim against ISI for the
satisfaction of the GP Strategies obligations. For accounting purposes, these
transactions were treated as integral parts of the Asset Sale Transactions and
accordingly, the obligations remained on the balance sheet until the closing of
the transaction on March 17, 2004, at which time the amount of such obligations
were recognized as extinguished for accounting purposes.

Note 5. Agreement with the Red Cross

The Company obtained human white blood cells used in the manufacture of
ALFERON N Injection from several sources, including the Red Cross pursuant to a
supply agreement dated April 1, 1997 (the "Supply Agreement"). As of November
23, 1998, the Company owed the Red Cross approximately $1.46 million plus
interest at the rate of 6% per annum accruing from April 1, 1998 (the "Red Cross
Liability") for white blood cells purchased pursuant to the Supply Agreement.

Pursuant to an agreement dated November 23, 1998, the Company granted
the Red Cross a security interest in certain assets to secure the Red Cross
Liability, issued to the Red Cross 300,000 shares of common stock and agreed to
issue additional shares at some future date as requested by the Red Cross to
satisfy any remaining amount of the Red Cross Liability. The Red Cross agreed
that any net proceeds received by it upon sale of such shares would be applied
against the Red Cross Liability. In January 1999, the Company granted the Red
Cross a security interest (the "Security Interest") in, among other things, the
Company`s real estate, equipment inventory, receivables, and New Jersey net
operating loss carryovers to secure repayment of the Red Cross Liability, and
the Red Cross agreed to forbear from exercising its rights under the Supply
Agreement, including with respect to collecting the Red Cross Liability until
June 30, 1999 (which was subsequently extended until December 31, 1999). On
December 29, 1999, the Company, the Red Cross and GP Strategies entered in an
agreement pursuant to which the Red Cross agreed that until September 30, 2000
it would forbear from exercising its rights under (i) the Supply Agreement,
including with respect to collecting the Red Cross Liability, and (ii) the
Security Interest. In connection with the Asset Sale Transactions (see Note 7),
the Company, HEB and the Red Cross entered into an agreement pursuant to which
the Red Cross agreed to forbear from exercising its rights until May 31, 2003
and the Red Cross agreed to accept HEB common stock with a guaranteed value of
$500,000 in full settlement of all of the Company`s obligations to the Red
Cross. On June 2, 2003, HEB delivered the HEB common stock to the Red Cross in
accordance with HEB`s obligation under the terms of the forbearance agreement.
However the forbearance agreement provided that in addition to the issuance by
HEB of the HEB common stock to the Red Cross, HEB was obligated to register the
HEB common stock for resale and any shares of HEB shares received by the Red
Cross which remain unsold after May 31, 2004 may be put to HEB at a price of
$1.59 per share.

The Red Cross Liability was legally extinguished by HEB on June 2,
2003. The Asset Sale Transaction with HEB closed on March 17, 2004. If the
transaction had not closed, HEB would have had a claim against ISI for the
satisfaction of the Red Cross Liability. For accounting purposes, these
transactions were treated as integral parts of the Asset Sale Transactions and
accordingly, the obligations remained on the balance sheet until the closing of
the transaction on March 17, 2004, at which time the amount of such obligations
were recognized as extinguished for accounting purposes.


Note 6. Recently Issued Accounting Standards


In December 2004, the Financial Accounting Standards Board (FASB)
issued Statement of Financial Accounting Standards (SFAS) No. 123 (revised
2004), "Share-Based Payment" (SFAS 123R), which replaces SFAS No. 123,
"Accounting for Stock-Based Compensation," (SFAS 123) and supercedes APB Opinion
No. 25, "Accounting for Stock Issued to Employees." SFAS 123R requires all
share-based payments to employees, including grants of employee stock options,
to be recognized in the financial statements based on their fair values
beginning January 1, 2006, with early adoption encouraged. The pro forma
disclosures previously permitted under SFAS 123 no longer will be an alternative
to financial statement recognition. Under SFAS 123R, the Company must determine
the appropriate fair value model to be used for valuing share-based payments,
the amortization method for compensation cost and the transition method to be
used at date of adoption. The transition methods include prospective and
retroactive adoption options. The Company has begun, but has not completed,
evaluating the impact of the adoption of SFAS 123R on its results of operations.
In connection with evaluating the impact of SFAS 123R, the Company is
considering the potential implementation of different valuation methods to
determine the fair value of share-based compensation. The Company believes the
adoption of SFAS 123R will have a material impact on its results of operations,
regardless of the valuation method used. Currently, the Company does not have
any employee stock options outstanding.


Note 7. Agreement with Hemispherx Biopharma, Inc. ("HEB")

On March 11, 2003, the Company executed two agreements with HEB to sell
certain assets of the Company (the two asset sale transactions are hereinafter
jointly referred to as the "Asset Sale Transactions" and individually referred
to as the "First Asset Sale" and the "Second Asset Sale") and consummated the
First Asset Sale.

In the first agreement with HEB (the "First Asset Sale Agreement"), the
Company sold all of its inventory related to ALFERON N Injection(R) (the
"Product") and granted a three-year license for the production, manufacture,
use, marketing and sale of the Product in the United States.

For these assets, the Company:

(i) received 424,528 shares of HEB common stock (the "HEB Common
Stock") which had a Guaranteed Value (as defined in the First
Asset Sale Agreement) of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without
a Guaranteed Value; and

(iii)will receive a royalty equal to 6% of the net sales of the
Product.

In addition, HEB assumed $408,000 of ISI payables and certain other
obligations related to the Product. The consummation of the First Asset Sale
Agreement resulted in a gain of $1,149,112, which is included in the
consolidated statement of operations for the year ended December 31, 2003.

ISI received a service fee until October 31, 2003 for providing certain
transitional services. Such service fee was $560,101 for the year ended December
31, 2003. As of December 31, 2003, the Company sold all 487,028 shares of HEB
Common Stock and realized net proceeds of $1,207,000, resulting in a gain of
$447,337, which is included in the consolidated statement of operations for the
year ended December 31, 2003.

In the second agreement with the Company (the "Second Asset Sale
Agreement"), which was consummated on March 17, 2004, the Company sold to HEB
all of its rights to the Product and other assets related to the natural alpha
interferon business including, but not limited to, real estate, machinery and
equipment. For these assets, the Company:

(i) received 424,528 shares of HEB Common Stock which has a
Guaranteed Value (as defined in the Second Asset Sale Agreement)
of $675,000;

(ii) received an additional 62,500 shares of HEB Common Stock without
a Guaranteed Value; and

(iii)will receive a royalty equal to 6% of the net sales of any
products containing natural alpha interferon sold by HEB (or a
Marketing Partner, as defined in the Second Asset Sale
Agreement).


In addition, HEB satisfied the Company`s obligations to (i) the
American Red Cross in the amount of $1,435,000, (ii) GP Strategies Corp. in the
amount of $423,000, and (iii) MD Sass in the amount of $644,000 (for unpaid
local property taxes and water and sewer charges). The consummation of the
Second Asset Sale Agreement resulted in a gain of $2,875,282, which is included
in the consolidated condensed statement of operations for the quarter ended
March 31, 2004. Through March 31, 2004, no shares received from the Second Asset
Sale Agreement were sold. As of December 31, 2004, the Company sold all of the
shares of HEB common stock and realized net proceeds of $1,935,683, resulting in
a gain on the sale of the HEB common stock of $270,048.

Note 8. Note Receivable - Agreement with Amphioxus Cell
Technologies, Inc. ("Amphioxus")

On March 20, 2003, the Company entered into a collaterialized note
agreement, as amended (the "Note") with Amphioxus to advance up to $500,000.
Pursuant to the Note, through June 30, 2005, the Company advanced $475,000. The
Note is due on September 30, 2005, bears interest at the rate of 10% per annum
and is collaterialized by all of the assets of Amphioxus. In addition, the
Company received a warrant, exercisable until March 2008, to purchase for
$100,000, an aggregate of 20% of the common stock of Amphioxus on a fully
diluted basis. The warrant is valued at $15,000, and such value is prorated
based on the amount of monies advanced and was amortized as interest income over
the original term of the Note.

On October 17, 2003, ISI and ACT entered into a non-binding letter of
intent pursuant to which ISI (or a wholly owned subsidiary of ISI) will acquire
ACT.

The Letter of Intent is subject to the execution of definitive documents
and final due diligence. There can be no assurance that a definitive agreement
will be consummated.

At December 31, 2004, the Company set up a provision against
the collectibility of the note and related interest due from ACT, due to the
uncertainty of the collectibility of such note and interest and to reflect its
estimated fair value. In addition, at March 31, 2005, the Company wrote off the
carrying value of the ACT warrant.


Note 9. Notes Payable

In August 2002, the Company completed a private placement of $500,000
of convertible notes to accredited investors. Each note is convertible into the
Company`s common stock at a price of $.05 per share (subject to adjustment to
70% of the market price of the Company`s common stock under certain
circumstances) and bears interest at the rate of 10% per annum. A $250,000
convertible note was due January 31, 2003 and the other $250,000 of the
convertible notes were due December 31, 2003. For each $100,000 principal amount
of notes issued, the investors received warrants to purchase an additional 10.2
million shares of the Company`s common stock exercisable at $.01 per share. The
warrants were valued at $400,000 and are amortized as interest expense over the
terms of the respective notes. The conversion of the convertible notes and the
exercise of the warrants are subject to approval by the shareholders of the
Company of the availability of a sufficient number of authorized common shares.
The terms of the notes, as amended, include the Company obtaining stockholder
approval by December 31, 2005 to increase its authorized shares so that the
number of authorized but unissued common shares is at least 200% of the number
of common shares issuable on conversion of the notes and exercise of the
warrants. Failure to obtain stockholder approval for the increase in the
authorized number of shares and to file with the Delaware Secretary of State an
amendment to the Company`s Certificate of Incorporation, on or before December
31, 2005 to increase its authorized shares, would require the Company to make
cash payments to each warrant holder, for each 30-day period such approval has
not been obtained, equal to the difference between the exercise price and volume
weighted average market price (for that 30-day period) for all warrants not
exercisable because of the failure to obtain the approval. Further the note
holders have registration rights whereby, for the period commencing April 30,
2004 but no later than December 31, 2005, upon written request from at least 50%
of the holders of the shares issuable upon the exercise of the warrants, the
Company is to file a registration statement within 30 days and have such
registration statement declared effective 90 days thereafter, to register the
common shares underlying the convertible notes and warrants. The Company`s
failure to file a registration statement or have one declared effective by the
required dates would result in the Company paying liquidated damages to each of
the above note-holders in an amount equal to 2% of the outstanding principal
amount of the convertible notes per month for each 30 day period or part
thereof, a registration statement was not filed. In addition, these notes are
convertible into common stock at a beneficial rate. The beneficial conversion
feature was valued at $100,000 and accounted for as debt discount and was
amortized over the term of the notes. The $250,000 note due on January 31, 2003
was repaid in full (including accrued interest) in November 2003. Of the
$250,000 notes which were due December 31, 2003, $ 25,000 was repaid (including
accrued interest) in May, 2004 and the remaining $ 225,000 are still unpaid.

Note 10. Antidilution Obligation

During the quarter and six months ended, June 30, 2005, the Company took a
charge of $310,305 for a potential antidilution obligation related to certain
warrants. A principal stockholder of the Company agreed to contribute shares of
common stock in settlement of the potential antidilution obligation, on the
basis of one share for each two warrants, pursuant to which 4,361,738 shares
were issued by the principal stockholder. The Company determined the amount of
the charge based on the closing price of the common stock on the date the
stockholder agreed to issue the shares. This amount was included in general and
administrative expenses for the quarter and six months ended, June 30, 2005.








INTERFERON SCIENCES, INC. AND SUBSIDIARY

MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS


ISI was incorporated in 1980 and until March 11, 2003, ISI was a
biopharmaceutical company which studied, manufactured, and sold ALFERON N
Injection(R), a highly purified, multi-species, natural-source alpha interferon
product (the "Product"). ALFERON N Injection is approved by the FDA for the
treatment of certain types of genital warts and has been studied for its
potential use in the treatment of human immunodeficiency virus ("HIV"),
hepatitis C virus ("HCV"), and certain other indications. ISI has experienced
significant operating losses since its inception.

On March 11, 2003, ISI executed two agreements with HEB to sell certain
assets of ISI. In the First Asset Sale Agreement, ISI sold all of its inventory
related to ALFERON N Injection(R), ISI`s natural alpha interferon product
approved for the treatment of certain types of genital warts (the "Product"),
and granted a limited license for the production, manufacture, use, marketing
and sale of the Product in the United States. In the Second Asset Sale
Agreement, which was consummated on March 17, 2004, ISI sold to HEB all of its
rights to the Product and other assets related to the Product including, but not
limited to, real estate, machinery and equipment.

On October 17, 2003, ISI and Amphioxus Cell Technologies, Inc. ("ACT")
entered into a non-binding letter of intent pursuant to which ISI (or a wholly
owned subsidiary of ISI) will acquire ACT. ACT is a biotechnology company that
applies liver biology solutions to problems in drug discovery and human
therapeutics. The letter of intent is subject to the execution of definitive
documents and final due diligence. (See Note 8).

Liquidity and Capital Resources

For the assets transferred to HEB pursuant to the First Asset Sale
Agreement, ISI received 487,028 shares of HEB common stock and a royalty equal
to 6% of the net sales of the Product. As of December 31, 2003, ISI sold all
487,028 shares of HEB common stock and realized net proceeds of $1,207,000. In
addition, until October 31, 2003, ISI received a service fee for providing
certain transitional services to HEB and HEB assumed $408,000 of ISI payables
and certain other obligations related to the Product.

For the assets transferred to HEB pursuant to the Second Asset Sale
Agreement, which was consummated on March 17, 2004, ISI received an additional
487,028 shares of HEB Common Stock. As of December 31, 2004, ISI sold all of the
487,028 shares of HEB common stock and realized net proceeds of approximately $
1,936,000. In addition, HEB satisfied certain obligations relating to the real
estate, machinery and equipment of ISI which aggregated approximately
$2,500,000.

At June 30, 2005, the Company had approximately $ 1,312,000 in cash and
cash equivalents. Until utilized, such cash and cash equivalents are being
invested principally in short-term interest-bearing investments.

Based on the Company`s estimates of revenues, expenses, and the timing
of repayment of creditors, management believes that the cash presently available
will be sufficient to enable the Company to continue its activities through June
30, 2006. However, actual results may differ materially from such estimate, and
no assurance can be given that additional funding will not be required sooner
than anticipated or that such additional funding will be available when needed
or on terms acceptable to the Company. Insufficient funds will require the
Company to curtail or terminate its activities.

The Company`s Common Stock is traded in the over-the-counter market and
quoted on the Pink Sheets, which may have a material adverse effect on the
liquidity of its Common Stock and on its ability to obtain additional financing.

Results of Operations

Six Months Ended June 30, 2005 Versus Six Months Ended June 30, 2004

For the six months ended June 30, 2005 and 2004, the Company recorded
royalty income from HEB of $30,298 and $31,808, respectively.

General and administrative expenses for the six months ended June 30, 2005
were $783,131 as compared to $469,863 for the same period in 2004. Of the
$313,268 increase, $310,305 resulted from a charge taken for potential
antidilution obligations relating to certain warrants and the remaining increase
of $2,963 was due to increases in certain operating expenses offset by decreases
in depreciation expense and property taxes.

Interest income (expense), net, for the six months ended June 30, 2005 was
income of $692 as compared to $9,369 for the six months ended June 30, 2004.

For the six months ended June 30, 2004, the Company recorded a gain on the
sale of assets to HEB of $2,875,282.

For the six months ended June 30, 2004, the Company recorded a gain on the
sale of HEB common stock of $270,048.

For the six months ended June 30, 2004, the Company recorded $ 52,470 of
income tax expense based upon the alternative minimum tax for federal tax
purposes.

As a result of the foregoing, the Company incurred a net loss of $752,141
and earned net income of $2,664,174 for the six months ended June 30, 2005 and
2004, respectively.

Three Months Ended June 30, 2005 Versus Three Months Ended June 30, 2004

For the three months ended June 30, 2005 and 2004, the Company recorded
royalty income from HEB of $14,298 and $17,068, respectively.

General and administrative expenses for the three months ended June 30,
2005 were $526,453 as compared to $196,469 for the same period in 2004. Of the
$329,984 increase, $310,305 resulted from a charge taken for potential
antidilution obligations relating to certain warrants and the remaining increase
of $19,679 was due to increases in certain operating expenses.

Interest income (expense), net, for the three months ended June 30, 2005
was income of $156 as compared to $2,479 for the three months ended June 30,
2004.

For the three months ended June 30, 2004, the Company recorded a gain on
the sale of HEB common stock of $270,048.

As a result of the foregoing, the Company incurred a net loss of $511,999
and earned net income of $93,126 for the three months ended June 30, 2005 and
2004, respectively.

Forward-Looking Statements

This report contains certain forward-looking statements reflecting
management`s current views with respect to future events and financial
performance. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those in
the forward-looking statements, including, but not limited to, the risk that the
Company will run out of cash and the uncertainty of obtaining additional funding
for the Company, all of which are difficult to predict and many of which are
beyond the control of the Company.






INTERFERON SCIENCES, INC. AND SUBSIDIARY

PART II. OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K

(b) Reports on Form 8-K

There were no reports of Form 8-K filed during the three months
ended June 30, 2005.


INTERFERON SCIENCES, INC.

June 30, 2005




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed in its behalf by the
undersigned thereunto duly authorized.



INTERFERON SCIENCES, INC.




DATE: August 14, 2005 By: /s/ Lawrence M. Gordon
Lawrence M. Gordon
Chief Executive Officer




DATE: August 14, 2005 By: /s/ Donald W. Anderson
Donald W. Anderson
Controller






CERTIFICATIONS

I, Lawrence M. Gordon, certify that:

1. I have reviewed this quarterly report on Form 10-Q/SB of Interferon Sciences,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant`s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;

b) evaluated the effectiveness of the registrant`s disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5. The registrant`s other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant`s auditors and the audit committee of
registrant`s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant`s ability to
record, process, summarize and report financial data and have
identified for the registrant`s auditors any material weaknesses in
internal controls; and

b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant`s
internal controls; and

6. The registrant`s other certifying officer and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: August 14, 2005

/s/ Lawrence M. Gordon
----------------------
Lawrence M. Gordon
Chief Executive Officer






CERTIFICATIONS

I, Donald W. Anderson, certify that:

1. I have reviewed this quarterly report on Form 10-Q/SB of Interferon Sciences,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant`s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;

b) evaluated the effectiveness of the registrant`s disclosure controls
and procedures as of a date within 90 days prior to the filing date of
this quarterly report (the "Evaluation Date"); and

c) presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

5. The registrant`s other certifying officer and I have disclosed, based on our
most recent evaluation, to the registrant`s auditors and the audit committee of
registrant`s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant`s ability to
record, process, summarize and report financial data and have
identified for the registrant`s auditors any material weaknesses in
internal controls; and

b) any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant`s
internal controls; and

6. The registrant`s other certifying officer and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: August 14, 2005

/s/ Donald W. Anderson
----------------------
Donald W. Anderson

[weierHai]

hallo armselig,

war von dem Bericht ebenfalls enttäuscht, aber

in der 2. Verkaufsvereinbarung an HEB wurde vereinbart, daß eine 6% Umsatzprovision an allen vermarkteten und verkauften Produkten , welche natural alpha interferon enthalten durch HEB gezahlt wird. Die REchte scheinen nun endgültig an HEB abgetreten worden zu sein. HEB hat zusätzlcihe Schulden von IFS beglichen.
Die geplane ÜBernahme von Amphioxus Cell TEchnologies ( noch nihct unter DAch und Fach!!) lediglich ein non binding letter of intend werden anscheinend von Insidern positiv bewertet. DAs HAuptaugenmerk liegt meines Erachtens jedoch in der Vermarktung von Alferon und seinen Ablegern. Habe schon mehrfach positive Studien von Alferon gegen die Vogelgrippe gelesen. Sollten hier die zusätzlichne Tests, welche im Moment in HongKong laufen weiterhin als positiv herausstellen, und das Produkt preislich der immensen NAchfrage entgegenkommen, so könnte hier meines Erahtens der Hauptgrund für die vergangene Kursbewegung gen Norden verantwortlich sein. Die Vogelgrippe ist weltweit auf dem Vormarsch. Aktuell in Rußland und Experten rechnen bei uns durch die Zugvögel ebenfalls mit dem Ausbruch der Seuche. Sollte es sich bewahrheiten, daß das Produkt hält was es verspricht, und die staatl. Gesundheitsbehörden das Medikament von IFS oder auch HEB kaufen .....

den Rest überlass ich euren Gedanken. Aber auch gegen die Seuche HIV soll das Präparat helfen. Also alles in allem bleibt IFS anscheinend ein interessantes Investment. ODer warum wurden in den letzten Monaten die Kurse langsam nach oben gezogen um sihc entsprechend zu positionieren, wenn seitens der FDA eine erste Zulassung bis Ende September erwartet wird ( hier nur gegen Warzeln)
Die Zahlen waren wirklihc nihct berauschend, den Kurs hingegen scheint es nicht zu stören; irgendwie merkwürdig oder nicht
also weiterhin die Augen auf
bis dann der wei0e Hai

[weierHai]

HAllo zusammen,

ab heute wird IFS nicht merh nur OTC gehandelt sondern unter OTC BB. Bulletin Board) Lt. Definition sind die dort eingestellten Preise als fix zu sehen während unter OTC die Preise nicht unbedingt marktgerechte Preise darstellen. Vielleihct kommt jetzt ein wenig Seriösität in den Titel. Wäre uns allen zu wünschen und mal mehr Infos zu den Produkten der Alferon Familie. Bin immer noch optimistisch bzgl. des Vogelgrippe Medikamentes, welches glaub ich zumindest zur Zeit in Honh Kong intensiv getestet wird.

bis dann

der weiße Hai

[Tornado 34]

Hallöchen. Nun bin ich wieder zurück.
Na wer sagts denn, ich war ja nie wirklich weg.
Seit meiner damaligen Empfehlung hat sich ifsc verzehnfacht, bzw, verfünfzehnfacht.

Ich war dabei

Wer noch?

Jetzt aber etwas anderes:

Der nächste Run steht an.....

OSEE: WKN 899519, OTCBB, OSEE

SCHAUT EUCH DEN CHART MAL AN.

Weiterhin IFSC viel Erfolg. Habe meinen 12fachen Gewinn mitgenommen und verabschiede mich nun von IFSC.

Grüsse, Torni

[armselig]

Hallo,
das ist ja köstlich :
Gestern sind 15000 Stk zu 0,13 USD verkauft worden
das waren meine... die habe ich limitiert zu 0,15 USD eingegeben. Nachdem ich dann am gleichen Tag meinen Broker für den Verlust von 300USD verantwortlich gemacht habe, hatte ich meine Aktien wieder und das Geld war zurückgebucht..............
trotzdem blieb der Kurs auf 0,13 USD obwohl nie ein gewollter Handel zustande kam......
entweder sind so die Kuse mal schnell gedrückt worden, oder
meine Bank ist jetzt short

[Tornado 34]

Seid bloss vorsichtig. IFSC ist meiner Meinung nach überbewertet. Wenn man bedenkt das 20 mille Aktien ausstehen zu einem Kurs von 0,13.....
Cash ist weitaus weniger. Ich habe nun meinen Teil verkauft und bin happy:-)
Nun ist Zeit für neue Investments:

Morningstar Alert

OSEE
08-24-05 09:10 PM
Volume more than twice 30-day average
This stock experienced unusually high trading volume of 111,500 shares today; its average daily volume over the past 30 days was 36,467 shares. For details, go to
http://quicktake.morningstar.com/Stock/stockperformance.asp?…


Viel Erfolg

Grüsse Torni

[Schoenecker]

Ich dachte, der Tag der Abrechnung ist erst im März 2006. Somit ist das noch ein halbes Jahr und werde jetzt erst mal den Rest vom Sommer genießen.
Irgend wann, wird IFS noch mal richtig kommen, oder auch nicht.

Schöner Tag noch
Gruß Manuel

[ICELINE]

Hallo armselig,

Du brauchst dir wegen deiner Bank glaube ich keine Gedanken machen. Ich habe auch 15.000 Stück verkauft.

Ich gehe davon aus, daß die sich einfach vertan haben.
Lasse den Rest im Depot und warte auf bessere Zeiten ...

[armselig]

@iceline
Naja dann stimmt ja wenigsten der Handel von 15000Stk.

@all
Ich denke dass im März 2006 gar nichts kommt, die Patente und Rechte sind doch verkauft oder nicht??

[weierHai]

Hallzusammen,

warum schwächelt unsere IFS? Schaut euch mal HEB an. Die ziehen seit gestern stark an. Hauptprodukt ist die Alferon Familei von IFS. Ob es hier einen Zusammenhang gibt. Demnach wäre der momentane Absturz nicht nachvollziehbar. HEB wird im Moment stark gepusht. Müßte auch unserer IFS auf dei Beine helfen?
Meinungen erwüsncht,

mfg
derweißeHai

[weierHai]

Hallo IFS Gemeinde,

schaut euch bitte mal die News unter Hemispherx Biopharma an. Ich würde momentan auf keinen Fall verkaufen!!
News vom 01.09.2005

bis dann
der weiße Hai

[weierHai]

Hallo IFSC Gemeinde,

hier der aktuelle Stand der Entwicklungspipline bei HEB US in bezug auf Interferon, sieht vielversprechend aus oder seht ihr das anders?


Hepatitis C
Alferon N Injection®
Phase 3 Preparation (China)

West Nile Virus
Alferon N Injection®
Phase 2/3 Preparation - Investigator Sponsored (USA)

HIV
Alferon LDO®
Phase 2 Preparation (Africa)


Avian Flu Alferon N Injection® / Alferon LDO® Preclinical Studies

der weißeHai

[armselig]

@weierHai,
also ich habe immernoch im Hinterkopf, dass
Interferon seine Rechte verkauft hat.
Ich bin auch raus aus IFSC und denke der Kursanstieg hat mit dem
relisting zu tun.
Nun ... jetzt habe ich ein wenig Gewinn...
und das ist auch gut so
schönen Gruß
armselig

[weierHai]

Hallo IFS Gemeinde,

die Vogelgrippe läßt grüßen!! Schaut euch mal HEB US an. Hemispherx ist in den letzten Tagen explodiert, da Ampligen das Roche Produkt Tamiflu in seiner Wirkung unterstützt. Im Aktionär wurde in der aktuellen Ausgabe ein Bericht zum Thema Vogelgrippe verfaßt. Demnach ist Hemispherx gut positioniert. Lt. Aktionärsletter vom 01.09.05 wird auf der Internetseite sehr positive über die zukünftige Entwicklung von Alferon N, die Studien zur Bekämpfung der Vogelgrippe usw. berichtet.Heute steigt HEB US um 25,00% !!!
Davon sollte doch auch IFSC profitieren!!! Warten wir mal die nächsten Infos ab,
leider ist auf der HEB Seite kein Hinweis zu der Verpflechtung zu Interferon!!!

auf eine rosige Zukunft
der weißeHai

Anregungen und Einschätzungen erwünscht!!

[Snoopy]

Heute geht wieder was.
Frage ist, warum?

[weierHai]

HAllo Snoopy,

endlich mal wieder ein LEbenszeichen in diesem Thread. Also zu deiner Frage:
Schau Dir mal den Wert Hemispherx Biopharma an. Dieser hatte heute seinen Quartalsbericht veröffentlicht, zsätzlihc wurde mitgeteilt daß mit Ampligen und Alferon sehr gute Testergebnisse in Bezug auf Grippeschutzimpfung. Ampligen hat die Ergebnisse in Verbindung mit dem Medikament TAmiflu von Roche deutlich verbessert. Die WHO prüft aktuell inwieweit Alferon zur Bekämpfung der Vogelgrippe dienen kann. Auch hier ist man in einem fortgeschrittenen Stadium. Desweiteren stehen am 15.11.05 der Quartalsbericht an. Lt. HEB, welche eine Umsatzprov. an Inteferon in Höhe von 6,00% zahlen muß ist dieser jedoch im laufenden Quartal gefallen. Aber die zukünftige Entwicklung scheint positiv in Bezug auf Alferon zu sein. Da scheinen sich manche Insider noch schnell billig eindecken zu wollen bevor hier offizielle Meldungen bzgl. des Einsatzes von Alferon zur Bekämpfung der Vogelgrippe bestätigt wird.
Die Wirksamkeit war in den bisherigen Studien sehr hoch.

So nun warten wir mal ab welche News Interferon am 15.11.05 veröffentlciht.

der weiße Hai

[weierHai]

schaut Euch mal das heutige Volumen an ( 325.000 Aktien; Kurs im High 0,20)

der weißeHai

[polyhawk]

Sehr lecker... - ich werde wohl noch sehr lange weiter halten!

Ich glaube, dass hier wirklich was geht. Ich habe viel Zeit.


Gruss
POLYHAWK

[Snoopy]

Entweder wissen hier welche mehr oder kaufen auf Verdacht.

[polyhawk]

Weird!!

Signifikante Umasaetze, keine Mitnahmen und keine News...

Mein Einstiegskurs bei 4 Cent reizt zwar zum Ausstieg, aber die Kohle war ehedem schon abgeschrieben und nun koennten wir uns am Anfang eines neuen Inter-Hypes befinden. Die Betonung liegt auf dem Wort "koennten".

Mein persoenliches Fazit: Ich werde das Baby mittelfristig halten. Klappt es - geil, geht es in die Hose - who cares...

Hey TORNADO - die sueffisanten Worte zum Austieg damals klingen jetzt ein wenig schriller, oder!?


So oder so - Inter war und ist eine spannende Aktie, lets see...


Allen anderen Inter-Fans sende ich einen Gruss und wuensche uns good luck!


cu
POLYHAWK

[polyhawk]

@ Snoopy

Ich kann mir nicht vorstellen, dass hier jemand auf Verdacht kauft. Den Wert scheint weder jemand zu beachten noch zu verfolgen.

M.E. ist dies fundamental begruended oder nur ein kuenstlicher Hype. Die Umsaetze sind zwar extrem gestiegen, aber das eingesetzte Kapital ist noch immer verschwindend gering. Jeder besoffene Betuchte koennte diesen Anstieg nebenbei eintueten und lachen...

Sollten hier Leute mit Insider-Wissen am Werk sein, so handeln diese ziemlich doof - die aktuellen Kurse koennten mit geringen Verlusten runter gebasht werden, um dann erneut zu pushen.

Fazit: Was geht? Keine Ahnung! Was kommt? Keinen Plan? Was machen - abwarten und cool bleiben (nur fuer Zocker geeignet...)!


Macht wieder Spass im Inter-Land (zumindest heute)!

cu
POLYHAWK

[Snoopy]

@polyhawk: Ich meine schon, dass der Wert beobachtet wird. Eben nicht bei uns hier sondern in USA. Könnte aber durchaus sein, dass hier Insider am Werk sind. Wobei das Volumen für einen richtig großen Zock zu gering ist. Da würde sich wahrscheinlich auch durch Manipulation wenig abfischen lassen, da etliche, wie du, wohl eher im Wert drin bleiben würden.

[Snoopy]

Hmmm, heute wieder hohes Volumen bei faktisch kaum einer Kursveränderung. Die Aktie ist unheimlich.

[polyhawk]

; )

[weierHai]

Guten Abend IFS- Gemeinde,

am 15.12.05 gibt es mal wieder einen Conference Call von Hemispherx Biopharma. Vielleicht gibt es ja Neuigkeiten bezüglcih unseres "Babies"

we will see

bis dann
der weiße HAi

[weierHai]

HAllo zusammen ,

die gestrige Präsentation von HEB US dürfte in NY auf positive Resonanz bzgl. der zukünftigen Vermarktung von Alferon getroffen sein. Sonst wäre dieser heutige Move wohl nicht zu erklären.
so kann`s weitergehen.

mfg
der weiße Hai

[weierHai]

die korrektur seit mitte nov. scheint mit dem heutgien tage beendt zu sein. extrem hohes volumen 321000 stück + 25% !!!
Anscheinend legen sich ein paar "Insider" den Wert fürs nächste Jahr als Performancerakete ins Depot!!
wünsche noch allen IFSC Anhängern einen guten Rutsch!!

der weiße HAi

[Snoopy]

Was ist hier los?
Wer gibt plötzlich diese Zahl von Aktien ab?